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State and local health departments, in collaboration with 
CDC, continue to investigate a mumps outbreak that began 
in New York in June 2009 (1). The index case occurred in a 
boy aged 11 years who had returned on June 17 from a trip 
to the United Kingdom, where approximately 7,400 reports 
of laboratory-confirmed mumps were received by the Health 
Protection Agency in 2009.* He then attended a New York 
summer camp for tradition-observant Jewish boys, where he 
became symptomatic on June 28. Subsequently, other camp 
attendees and a staff member were reported to have mumps, 
and transmission continued in multiple locations when the 
camp attendees returned home. As of January 29, 2010, a total 
of 1,521 cases had been reported, with onset dates from June 
28, 2009, through January 29, 2010, a substantial increase 
from the 179 cases reported as of October 30, 2009 (1). The 
outbreak has remained confined primarily to the tradition-
observant Jewish community, with <3% of cases occurring 
among persons outside the community. The largest percentage 
of cases (61%) has occurred among persons aged 7–18 years, 
and 76% of the patients are male. Among the patients for whom 
vaccination status was reported, 88% had received at least 1 
dose of mumps-containing vaccine, and 75% had received 2 
doses. This is the largest mumps outbreak that has occurred in 
the United States since 2006 (2). Although mumps vaccination 
alone was not sufficient to prevent this outbreak, maintaining 
high measles, mumps, and rubella (MMR) vaccination coverage 
remains the most effective way to prevent outbreaks and limit 
their size when they occur.
Mumps cases included in this report were reported by 
January 29, 2010. Cases were classified according to the 
2008 case definition of the Council of State and Territorial 
Epidemiologists†; only cases of probable and confirmed mumps 
are included in this report. In the United States, the Advisory 
Committee on Immunization Practices (ACIP) recommends 
that children receive 2 doses of measles, mumps, and rubella 
(MMR) vaccine, with the first dose administered at 12–15 
months and the second dose near the time of school entry (at 
4–6 years).§ Methods used to obtain the vaccination status of 
patients have included parental report, review of vaccination 
cards, and verification from health-care providers. 
The 1,521 outbreak-related mumps cases have been reported 
from several counties in New York and New Jersey; local 
transmission is continuing (Figure). The majority (675 [44%]) 
of cases have been reported from New York City (primarily 
Brooklyn), followed by Orange County, New York (364 [24%]); 
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* Available at http://www.hpa.org.uk/hpr/archives/2010/news0210.htm#mmps. 
† An illness with acute onset of unilateral or bilateral tender, self-limited swelling 
of the parotid or other salivary glands, lasting at least 2 days, and without other 
apparent cause. Probable case: a case that meets the clinical case definition without 
laboratory confirmation and is epidemiologically linked to a clinically compatible 
case. Confirmed case: a case that 1) meets the clinical case definition or occurs in 
a patient with a clinically compatible illness and 2) is either laboratory confirmed 
or is epidemiologically linked to a confirmed case. Available at http://www.cdc.
gov/ncphi/disss/nndss/casedef/mumps_2008.htm.
§ ACIP recommends 2 doses of mumps-containing vaccine for all school-aged 
children (i.e., grades K–12) and for adults at high risk for disease (i.e., persons 
who work in health-care facilities, international travelers, and students at 
post–high school educational institutions). Health-care workers born in or 
after 1957 without laboratory evidence of immunity should receive 2 doses of 
mumps-containing vaccine, and those born before 1957 without laboratory 
evidence of immunity should consider receiving 1 dose. During outbreaks, ACIP 
recommends offering a second dose of vaccine to children aged 1–4 years (8).
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Rockland County, New York (298 [20%]); and four 
counties in New Jersey (159 [10%]). Twenty-five (2%) 
cases (reported during June 28–September 8) were 
associated with the summer camp in Sullivan County, 
New York; however, no additional cases occurred in 
the county after the camp ended in late August. Of 
the 1,521 patients, 1,477 (97%) are members of the 
tradition-observant Jewish community. Of the 44 
cases not associated with this religious community, 33 
have been reported from New York City; seven from 
New Jersey; two from Orange County, New York; 
and two from Rockland County, New York. Many 
of these outside cases have occurred among persons 
who have reported regular contact with members of 
the affected community.
Diagnostic laboratory testing for mumps (i.e., 
detection of mumps immunoglobulin M antibod-
ies by various methods, detection of mumps RNA 
by real-time reverse transcription–polymerase chain 
reaction, or isolation of mumps virus in cell culture) 
has been performed for 761 (50%) cases. Of these, 
385 (51%) cases are laboratory confirmed. 
Of the 1,518 patients whose age is known, 1,385 
(91%) are aged >6 years (Figure). The median age 
of patients is 15 years (range 3 months–90 years) 
and is similar in all areas with ongoing transmission 
except New Jersey, where the median age is 17 years. 
Of the 1,489 patients whose sex is known, 1,136 
(76%) are male. Sixty-five reports of complications 
from mumps have been received: orchitis (55 cases), 
pancreatitis (five cases), aseptic meningitis (two cases), 
transient deafness (one case), Bell’s palsy (one case), 
and oophoritis (one case). Nineteen hospitalizations 
from mumps have been reported; no deaths have 
occurred.
Vaccination status is known for 1,115 patients: 
966 (91%) of 1,062 patients aged ≤18 years and 149 
(33%) of 456 patients aged ≥19 years (Table). Of these 
patients, 976 (88%) had received at least 1 dose of 
mumps-containing vaccine before the outbreak, and 
839 (75%) had received 2 doses. Among patients aged 
7–18 years, the age group with the majority of cases 
and for whom 2 doses of MMR vaccine is recom-
mended, 93% had received at least 1 dose, and 85% 
had received 2 doses. The vaccination status of the 
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patients varies by location. The percentage of patients 
aged >6 years (for whom vaccination status is known) 
who had received 2 doses of mumps vaccine is highest 
in Orange County, New York (86%), followed by New 
York City (83%), New Jersey (76%), and Rockland 
County, New York (73%). 
Public health response measures in all affected 
areas have continued throughout the outbreak. 
Health-care providers have been notified about the 
ongoing outbreak, the importance of verifying that 
children have received all recommended vaccinations, 
and the need to offer vaccinations to adults with 
unknown vaccination status who do not have a his-
tory of mumps. State and local health departments 
also have worked with affected schools to enhance 
vaccination policies, including policies to exclude 
unvaccinated children from school during outbreaks 
and to isolate children at home for 5 days after onset 
of parotitis. Certain jurisdictions have encouraged 
providers to offer a second dose of MMR vaccine to 
children aged 1–4 years; however, this strategy has 
not been a focus of the public health response because 
FIGURE. Number (n = 1,494*) of reported confirmed or probable mumps cases,† by week of illness onset and age group — New York and New 
Jersey, June 2009–January 2010§
* Total cases reported: N = 1,521. Date of illness onset or age was missing for 27 cases (date of onset missing for 25 cases, age for two cases, and both date and age 
for one case).
† Case definitions available at http://www.cdc.gov/ncphi/disss/nndss/casedef/mumps_2008.htm.
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of the small proportion (4.9%) of cases reported in 
this age group.
Beginning on January 19, 2010, in Orange 
County, New York, public health officials began 
offering a third dose of MMR vaccine in three schools 
where, despite documentation of a high level of 2-dose 
coverage among students, transmission had continued 
for >2 months. This intervention is being carried 
out under an Institutional Review Board–approved 
protocol that provides for an evaluation of the impact 
of the intervention. 
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Editorial Note 
The mumps outbreak in the New York-New 
Jersey area has grown substantially, and anecdotal 
reports from certain affected areas suggest that the 
rate of new cases is not decreasing; the appearance of 
a downward trend in recent weeks (Figure) is partly a 
result of reporting delays. The outbreak is occurring 
almost exclusively in a specific religious community, 
and no cases outside this community have resulted 
in sustained transmission. 
Like the mumps outbreaks that occurred in 2006 
(2), much of the current outbreak is occurring in 
congregate settings, where prolonged, close contact 
among persons might be facilitating transmission. 
Within the affected religious community, cases have 
occurred predominantly among school-aged boys, 
who attend separate schools from girls. The higher 
rate among boys might be a result of the additional 
hours that boys in this community spend in school 
compared with girls, including long periods in large 
study halls, often face-to-face with a study partner. 
In addition, transmission in the community over-
all might be facilitated by relatively large household 
sizes. According to the 2000 U.S. Census, the mean 
household size in one of the affected communities 
was 5.7, compared with a mean U.S. household size 
of 2.6. The limited transmission to persons outside 
the community might be a result of the relatively less 
interpersonal contact between persons inside and 
outside the community.
Although the school settings and large household 
sizes might be promoting transmission, the high vac-
cination coverage in the affected community likely is 
limiting the size of the outbreak. In addition, high 
vaccination coverage in surrounding communities is 
the most plausible reason that the few cases outside 
of the affected community have not caused other 
outbreaks. 
In this outbreak, as in other recent mumps out-
breaks among highly vaccinated populations (3), 
most cases have occurred in vaccinated persons. The 
mumps vaccine has greatly reduced the incidence of 
mumps in the United States. From 1967, when the 
mumps vaccine was first licensed, to the early 2000s, 
the number of reported cases decreased from 186,000 
to <500 annually (2). Nonetheless, the effectiveness of 
the mumps component of the MMR vaccine is lower 
than that of the measles and rubella components. 
TABLE. Vaccination status of patients with confirmed or probable mumps,* by age group and number of mumps-containing vaccine doses received 




Total<16 mos 16 mos–6 yrs 7–18 yrs ≥19 yrs Unknown
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
0 21 (80.8) 32 (29.9) 56 (6.0) 30 (6.6) 0 — 139 (9.1)
1 3 (11.5) 33 (30.8) 72 (7.8) 29 (6.4) 0 — 137 (9.0)
2 0 — 36 (33.6) 713 (76.7) 90 (19.7) 0 — 839 (55.2)
Unknown 2 (7.7) 6 (5.6) 88 (9.5) 307 (67.3) 3 (100.0) 406 (26.7)
Total 26 (100.0) 107 (100.0) 929 (100.0) 456 (100.0) 3 (100.0) 1,521 (100.0)
* Case definitions available at http://www.cdc.gov/ncphi/disss/nndss/casedef/mumps_2008.htm.
† Case total with onset date through January 29, 2010. The outbreak is ongoing.
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Estimates of the effectiveness of the mumps vaccine 
have varied in previous studies, ranging from 73% to 
91% after 1 dose and from 79% to 95% after 2 doses 
(3–5). At least one study found 2 doses to be more 
effective than 1 dose (6). 
Public health officials began offering a third dose 
of vaccine to students in certain schools in Orange 
County, New York, because mumps transmission had 
continued among students, despite their high rate of 
2-dose coverage. Although a previous study indicated 
that a third dose of MMR vaccine for seronegative 
college students resulted in rapid seroconversion with 
a low rate of IgM response, which is indicative of 
an anamnestic immune response (7), ACIP has not 
recommended a third dose, and no data exist on the 
effectiveness of a third dose in either reducing the risk 
for mumps or altering the course of an outbreak. Data 
obtained from use of the third dose of MMR vaccine 
in Orange County might be used to guide future 
options for mumps outbreak control in settings with 
high 2-dose coverage.
This outbreak emphasizes that mumps outbreaks 
can occur in highly vaccinated populations. Although 
several factors play a role in mumps control in the 
United States (Box), maintenance of high 2-dose 
MMR vaccine coverage remains the most effective way 
to prevent and limit the size of mumps outbreaks. 
What is already known on this topic?
The largest U.S. mumps outbreak since 2006 began at 
a summer camp in New York in June 2009. By October 
30, 2009, the outbreak included 179 confirmed 
and probable cases, primarily among members of 
certain highly vaccinated, tradition-observant Jewish 
communities.
What is added by this report?
As of January 29, 2010, the outbreak included 1,521 
cases, 97% of which had occurred in members of 
the same tradition-observant religious community. 
Among patients for whom vaccination status was 
reported, 88% had received at least 1 dose of mumps-
containing vaccine, and 75% had received 2 doses.
What are the implications for public health practice?
Although vaccination alone does not prevent all 
mumps outbreaks, maintaining high measles, mumps, 
and rubella (MMR) vaccination coverage remains the 
most effective way to prevent outbreaks and limit 
their size when they occur.
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BOX. Principles for mumps control 
•	 Timely	vaccination	with	2	doses	of	measles,	
mumps, and rubella (MMR) vaccine.
•	 High	awareness	among	health-care	providers	
that mumps can occur, even in communi-
ties with high 2-dose MMR vaccination 
coverage.
•	 Ongoing	surveillance	and	prompt	reporting	
of mumps cases to public health officials.
•	 Isolation	 of	 persons	 with	 suspected	 and	
confirmed mumps for 5 days after onset of 
parotitis. 
•	 In	 congregate	 settings	 such	 as	 colleges	 and	
schools where mumps can spread rapidly: 
early recognition, diagnosis, and public health 
intervention.
•	 During	outbreaks:	1	dose	of	MMR	vaccine	
for adults and children whose vaccination 
status is unknown or who have not received 
the number of MMR doses recommended by 
the Advisory Committee on Immunization 
Practices; consideration of a second dose of 
MMR vaccine for children aged 1–4 years and 
adults who have received 1 dose (8).
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12, 5 days after receiving the vaccine, she reported a 
headache, malaise, and low fever, which persisted for 
2 days. The mother did not seek medical care for her 
symptoms. 
On April 15, 2009, the mother’s infant, aged 23 
days, developed fever, and irritability and refused to 
nurse. The next day, the infant exhibited seizure-like 
activity and was admitted to the hospital for evaluation 
of possible meningoencephalitis. Upon admission, the 
infant experienced unilateral left upper extremity 
clonic convulsions of increasing frequency requiring 
intravenous diazepam (0.15 mg). Perioral cyanosis 
was noted and oxygen saturation measured by arterial 
blood gas was pO2 60 (normal: pO2 80–100). A chest 
radiograph showed no infiltrate. Peripheral white 
blood cell (WBC) count was 25,400/mm3 (normal: 
5,000–20,000 WBC/mm3) and platelet count was 
393,000/mm3 (normal: ≥150,000 platelets/mm3). 
Laboratory examination of CSF was unremarkable, 
with a WBC count of 1/mm3 (normal: 0–5 WBC/
mm3), slight elevation of protein (67 mg/dL [normal: 
15–45 mg/dL]), and decreased glucose concentration 
(37 mg/dL [normal: 42–78 mg/dL]). Gram stain of 
the CSF specimen revealed no bacteria. The infant 
received oxygen therapy, intravenous dipyrone (0.1 
mL every 6 hours) and phenytoin (10 mg every 12 
hours), and empiric treatment for bacterial infec-
tion with ampicillin and gentamicin. On April 18, 
empiric acyclovir treatment was added. No specimens 
for bacterial or fungal cultures were obtained. Other 
etiologies for meningoencephalitis were ruled out by 
testing of serum and CSF samples for dengue-specific 
IgM; viral culture for herpes simplex, cytomegalovi-
rus, and varicella; and RT-PCR for enteroviruses, all 
of which were negative.
The infant alternated between periods of somno-
lence and irritability, without clinical improvement. 
On April 19, convulsions became more frequent (one 
episode every 10 minutes) and difficult to control, 
with persistent perioral cyanosis, resulting in trans-
fer to the pediatric ICU for continuous infusion of 
anticonvulsants and monitoring of oxygen saturation. 
A second CSF examination showed a WBC count of 
128/mm3, a protein concentration of 106 mg/dL, and 
In April, 2009, the state health department of Rio 
Grande do Sul, Brazil, was notified by the Cachoeira 
do Sul municipal health department of a case of 
meningoencephalitis requiring hospitalization in an 
infant whose mother recently had received yellow 
fever vaccine during a postpartum visit. The Field 
Epidemiology Training Program of the Secretariat of 
Surveillance in Health of the Brazilian Ministry of 
Health assisted state and municipal health depart-
ments with an investigation. This report summarizes 
the results of that investigation, which determined 
that the infant acquired yellow fever vaccine virus 
through breast-feeding. The mother reported 2 days 
of headache, malaise, and low fever occurring 5 days 
after receipt of yellow fever vaccine. The infant, who 
was exclusively breast-fed, was hospitalized at age 
23 days with seizures requiring continuous infusion 
of intravenous anticonvulsants. The infant received 
antimicrobial and antiviral treatment for meningoen-
cephalitis. The presence of 17DD yellow fever virus 
was detected by reverse transcription–polymerase 
chain reaction (RT-PCR) in the infant’s cerebrospinal 
fluid (CSF); yellow fever–specific immunoglobulin 
M (IgM) antibodies also were present in serum and 
CSF. The infant recovered completely, was discharged 
after 24 days of hospitalization, and has had normal 
neurodevelopment and growth through age 6 months. 
The findings in this report provide documentation 
that yellow fever vaccine virus can be transmitted via 
breast-feeding. Administration of yellow fever vaccine 
to breast-feeding women should be avoided except 
in situations where exposure to yellow fever viruses 
cannot be avoided or postponed.
On March 23, the mother, aged 22 years, deliv-
ered a healthy female infant at 39 weeks’ gestational 
age by elective cesarean delivery. During that same 
month, a yellow fever epidemic had spread to a non-
endemic area in Rio Grande do Sul state where the 
mother resided (1). On April 7, when the mother 
was 15 days postpartum, she visited her health-care 
provider to have the sutures removed from her cae-
sarean incision. While in the provider’s office, she 
received 17DD yellow fever vaccine. She had not 
been vaccinated for yellow fever previously. On April 
Transmission of Yellow Fever Vaccine Virus Through 
Breast-Feeding — Brazil, 2009
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a glucose concentration of 24 mg/dL. Computerized 
tomography of the head demonstrated bilateral sym-
metrical areas of diffuse low density suggestive of 
inflammation consistent with encephalitis. 
After the second CSF examination on April 19, 
the mother mentioned receiving yellow fever vaccine 
8 days before the infant’s onset of symptoms, and a 
serum and CSF sample from the infant were sent 
to the arbovirus reference laboratory at Adolfo Lutz 
Institute in São Paulo, Brazil, to test for the presence of 
17DD yellow fever vaccine virus. Yellow fever-specific 
IgM antibodies were detected in serum and CSF. 
Yellow fever viral RNA was amplified by RT-PCR 
(2,3) from a CSF specimen collected on April 19; the 
nucleotide sequence of the amplified PCR product 
was identical to 17DD yellow fever vaccine virus. 
No breast milk or maternal serum was collected for 
yellow fever virus testing. 
The infant recovered completely and was dis-
charged from the hospital without sequelae on May 
10, 2009. Follow-up of the infant showed normal 
neurodevelopment and growth through age 6 months. 
The Brazilian Committee on Vaccine-Associated 
Adverse Events classified the child’s encephalitis as 
yellow fever vaccine–associated neurologic disease. To 
rule out the possibility that the infant had received 
yellow fever vaccine inadvertently, the investigators 
reviewed all procedures documented in the medical 
record performed between the infant’s birth and onset 
of symptoms. The child had received intramuscular 
vitamin K and hepatitis B vaccine on the day of birth. 
Two other children born on the same day had received 
hepatitis B vaccine from the same lot of vaccine as the 
one registered in the child’s vaccination record, and 
neither experienced similar symptoms. 
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Editorial Note
This report describes the first laboratory-confirmed 
case of yellow fever vaccine–associated neurologic 
disease occurring in an infant secondary to the 
transmission of yellow fever vaccine virus through 
breast milk. The infant described in this report also 
is the youngest reported case of yellow fever vaccine–
associated neurologic disease. The presence of yellow 
fever-specific IgM in CSF, and 17DD yellow fever 
vaccine viral RNA in the CSF of the infant indicates 
transmission and infection with yellow fever vac-
cine. Following primary vaccination, IgM antibodies 
generally appear 4–7 days after receipt of vaccine (4). 
Maternal IgM antibodies can be excreted in breast 
milk and the presence of serum IgM in the infant 
alone is not diagnostic of yellow fever virus infection. 
The detection of IgM antibodies in the infant’s CSF 
indicates intrathecal antibody production in response 
to a nervous system infection because IgM does not 
normally cross the blood brain barrier (5). 
Based on the mother’s receipt of yellow fever vac-
cine on April 7, and onset of symptoms in the infant 
on April 15, the infant’s infection likely occurred 
during the expected peak of viremia following vaccina-
tion. Neurologic adverse events, including encephali-
tis, have been described previously in association with 
yellow fever vaccination; children aged <6 months 
have the highest incidence of vaccine-associated 
neurologic events (6). However, only one previous 
episode of encephalitis, which was not confirmed as 
vaccine-associated, has been described in an infant 
exposed to yellow fever vaccine virus through breast-
feeding (Public Health Agency of Canada, personal 
communications, 2009). 
Yellow fever vaccine is a live, attenuated virus prep-
aration made from various strains of the 17D yellow 
fever virus lineage. In Brazil, yellow fever vaccine from 
the 17DD strain is produced by Bio-Manguinhos, a 
public sector vaccine manufacturer of the Oswaldo 
Cruz Foundation of the Brazilian Ministry of Health. 
Yellow fever vaccine–associated neurologic disease 
(YEL-AND, formerly known as postvaccinal encepha-
litis) is reported to occur at a rate of 0.4 cases per 
100,000 persons vaccinated in the U.S. population, 
with highest rates reported among persons aged ≥60 
years (1.6 per 100,000) (6). However, the incidence 
among infants aged <6 months has been estimated 
as 0.5–4.0 cases per 1,000 infants vaccinated (4). For 
this reason, administration of 17D-derived yellow 
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fever vaccines is contraindicated in infants aged <6 
months (4,7,8).
Yellow fever virus, either wild-type or 17D, has not 
been reported to have been isolated from or detected 
in human breast milk. West Nile virus (WNV), 
another flavivirus, has been detected in milk from 
WNV-infected, lactating women (9), and one case of 
probable WNV transmission through breast-feeding 
has been reported (10). The actual risk for 17DD 
virus transmission through breast-feeding cannot be 
characterized because the number of breast-feeding 
women who have been vaccinated without negative 
sequelae in their infants is unknown. Based on the 
theoretical risk for yellow fever vaccine virus transmis-
sion through breast milk, the Advisory Committee on 
Immunization Practices recommends that yellow fever 
vaccination of nursing mothers be avoided, except 
when travel of nursing mothers to high-risk yellow 
fever–endemic areas cannot be avoided or postponed 
(7). Vaccine recommendations from the World Health 
Organization do not include considerations for breast-
feeding mothers (8).
In Brazil, yellow fever vaccination is recommended 
for all residents of municipalities considered at risk for 
yellow fever transmission, and for travelers to at-risk 
areas (1). As a result of this investigation, the Brazilian 
Ministry of Health is revising its recommendations to 
caution against administration of yellow fever vaccine 
to breast-feeding women, except in situations where 
the risk for contracting yellow fever is unavoidable. 
Further studies on excretion of 17DD virus in breast 
milk of vaccinated, lactating women would help to 
define a risk period for viral transmission in cases 
where vaccination of nursing mothers is necessary.
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What is already known on this topic?
Administration of yellow fever vaccine is contrain-
dicated in children aged <6 months because of 
increased risk for vaccine-associated encephalitis; 
the Advisory Committee on Immunization Practices 
cautions against vaccinating breast-feeding women 
to avoid the potential risk for transmission of yellow 
fever vaccine virus to breast-feeding infants.
What is added by this report?
This report describes laboratory-confirmed, breast-
feeding–associated transmission of 17DD yellow fever 
vaccine virus from a recently vaccinated mother; the 
affected infant developed postvaccinal encephalitis 
requiring hospitalization.
What are the implications for public health practice?
Health-care personnel should be aware that yellow 
fever vaccine virus can be transmitted through breast-
feeding, and administration of yellow fever vaccine to 
breast-feeding women should be avoided except in 
situations where exposure to circulating yellow fever 
viruses cannot be avoided.
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linkages with other health information systems, data 
quality and use, vaccine management, software and 
hardware capabilities, and report functions). All 56 
grantees were asked to complete the IISAR, and 52 
did so for 2008. The percentage of all U.S. children 
aged <6 years participating in each IIS was calculated 
by dividing the number of children aged <6 years 
participating in the IIS by the 2008 mid-year U.S. 
Census projection for all children aged <6 years.
Approximately 18 million U.S. children aged <6 
years (75% of all U.S. children in that age group) 
participated in an IIS in 2008, compared with 15 
million (65%) in 2006 (1). Of the 52 responding 
grantees, 22 grantees (42%) reported that >95% of 
children aged <6 years participated in the IIS (Figure), 
compared with 15 of 56 (27%) grantees in 2006. For 
2008, a total of 11 (21%) grantees reported child 
participation ranging from 80% to 94%, compared 
with 10 of 56 (18%) in 2006. 
In 2008, an estimated 23 million adolescents aged 
11–18 years (65% of all U.S. adolescents) participated 
in an IIS, compared with 22.3 million (66%) in 2006. 
Also in 2008, 54 million adults aged >19 years (24% 
of all U.S. adults aged >19 years) participated in an 
IIS, compared with 33.5 million (18%) in 2006. 
Nationally, 95 million persons of all ages (33% of 
the U.S. population) were participating in an IIS in 
2008. Overall, IIS participation for children aged <6 
years accounted for 19% of all participants in IISs, 
whereas adolescents and adults accounted for 25% 
and 57%, respectively.
IIS timeliness is measured by the interval between 
1) a child’s birth and the establishment of an IIS record 
and 2) administration of a vaccine and submission of 
its dose-related data to an IIS (2). In 2008, 71% of 
IISs reported that an IIS record had been established 
for newborn children within 6 weeks of birth (com-
pared with 69% in 2006) (1). For all vaccine doses 
administered and recorded in 2008 to children aged 
<6 years, 67% of all vaccine data were received and 
processed in the IIS within 30 days of vaccine admin-
istration, compared with 69% in 2006. 
Completeness of IIS data is measured by 1) assess-
ing IIS records for data on National Vaccine Advisory 
Committee (NVAC) core data elements (3) and 2) 
Immunization information systems (IISs) are 
confidential, computerized information systems that 
collect and consolidate vaccination data from multiple 
health-care providers, generate reminder and recall 
notifications, and assess vaccination coverage within 
a defined geographic area (1). A CDC program goal 
for 2010 is to achieve >95% participation in an IIS 
(defined as having two or more recorded vaccinations) 
among children aged <6 years. To monitor progress 
toward this goal, CDC annually surveys immuniza-
tion grantees in 50 states, five cities, and the District 
of Columbia, using the Immunization Information 
Systems Annual Report (IISAR). All 56 grantees were 
asked to complete the IISAR; 52 did so for 2008. This 
report highlights results from the 2008 IISAR, which 
indicated that 75% of all U.S. children aged <6 years 
(approximately 18 million children) participated in an 
IIS in 2008, an increase from 65% in 2006 (1). The 
majority of grantees (82%) reported that their IIS had 
the capacity to track vaccinations for persons of all 
ages, compared with 70% in 2006 (1). Data-quality 
measures of timeliness and completeness indicated 
that in 2008, 67% of IIS data were received and pro-
cessed within 30 days of vaccine administration, and 
data were reported for six of 17 core data elements 
in >90% of IIS records (both measures are similar to 
2006 results). Increased provider use of electronic 
health record systems can benefit IISs and their users 
by producing immunization records that are more 
timely and complete.
The 2008 IISAR, a self-administered, Internet-
based questionnaire, was made available to state and 
local immunization program managers in the 50 
states, five cities,* and the District of Columbia that 
receive funding under section 317 of the Public Health 
Service Act,† as part of an annual reporting require-
ment. As in previous years, respondents were asked 
about the number of children aged <6 years partici-
pating in the IIS; the number of health-care–provider 
sites participating; child, adolescent, and adult 
vaccination series completion and coverage; and 
programmatic and technical capabilities (e.g., data 
Progress in Immunization Information Systems — 
United States, 2008
* Chicago, Illinois; Houston, Texas; New York, New York; 
Philadelphia, Pennsylvania; and San Antonio, Texas.
† 42 USC Sect. 247b, project grants for preventive services. 
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determining the proportion of children aged 19–35 
months participating in an IIS who were recorded as 
having received the complete 4:3:1:3:3:1§ series of 
recommended vaccine doses. The first completeness 
measure is assessed by examining required core data 
elements (4) to determine the proportion that are 
>90% complete in IIS records. Core data elements are 
designed to standardize a set of patient demographic 
and vaccine event elements, which are necessary for 
identification and removal of duplicate records and 
data exchange with other health information systems 
(2,3). In 2008, very little or no change occurred in the 
percentage of data in IISs for nine of the 17 core data 
elements (compared with 2006) (1). (Table). 
The second completeness measure indicated 
that of the 4.4 million children aged 19–35 months 
participating in an IIS, an estimated 2.0 million 
(47%) had documentation in the IIS of having fully 
completed the recommended 4:3:1:3:3:1 vaccina-
tion series in 2008, compared with 45% in 2006 
(1). Completeness of IIS vaccination histories varied 
substantially by grantee. In 2008, 30% of children 
aged 19–35 months participating in an IIS who had 
an incomplete vaccination series were only 1 dose 
away from series completion. 
Reported by
J Kelly, V Heboyan, PhD, B Rasulnia, PhD, G Urquhart, MPH, 
Immunization Information Systems Support Br, National Center 
for Immunization and Respiratory Diseases, CDC.
Editorial Note
Grantees have made substantial progress towards 
CDC’s 2010 goal of >95% participation in an IIS by 
children aged <6 years. From 2006 to 2008, participa-
tion increased from 65% to 75%. This upward trend 
in participation suggests that IISs might be on target 
to meet the CDC 2010 goal. However, although 
participation rates have increased, data-quality issues 
continue to pose challenges. 
The push to include more adolescent and adult 
vaccination data in IISs, in addition to the complexi-
ties of receiving administrative data from multiple 
sources (e.g., vital records, health plans, billing sys-
tems, and Medicaid/Medicare), might have contrib-
uted to the lack of progress on data-quality measures. 
CDC’s current efforts to improve IIS data quality 
include collaboration with grantees and the American 
Immunization Registry Association to develop best 
practices for IIS functionality (5). CDC IIS sentinel 
sites¶ will begin to incorporate some of these guide-
lines within the next year. 
FIGURE. Percentage of children aged <6 years participating in the grantee 
immunization information system (IIS)* — United States, 50 states, five cities, and 
the District of Columbia,† 2008
* The percentage of all U.S. children aged <6 years participating in each IIS was calculated by 
dividing the number of children aged <6 years participating in the IIS by the 2008 mid-year 
U.S. Census projection for all children aged <6 years. 
† Chicago, Illinois (40%); District of Columbia (100%); Houston, Texas (54%); New York, New 
York (100%); Philadelphia, Pennsylvania (100%); and San Antonio, Texas (72%).








§ Includes 4 doses diphtheria and tetanus toxoids and acellular 
pertussis vaccines, 3 doses poliovirus vaccine, 1 dose measles, 
mumps, and rubella vaccine, 3 doses Haemophilus influenzae type 
B vaccine, 3 doses hepatitis B vaccine, 1 dose varicella. 
¶ Additional information available at http://www.cdc.gov/vaccines/
programs/iis/activities/sentinel-sites.htm.
What is already known on this topic?
Approximately 65% of all U.S. children aged <6 years 
(15 million children) participated in an immunization 
information system (IIS) in 2006.
What is added by this report?
In 2008, 75% of all U.S. children aged <6 years (approxi-
mately 18 million children) participated in an IIS.
What are the implications for public health practice? 
Enhanced interoperability between electronic health 
record systems and IISs can improve 1) the complete-
ness of immunization histories available to clinicians 
and public health practitioners, 2) the timeliness of 
immunization data submission to IISs, 3) the quality of 
IIS coverage assessments, and 4) the data available to 
other public health systems. 
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Although not directly comparable because of the 
differences in methodology and sampling techniques, 
comparison of results from IIS 4:3:1:3:3:1 series com-
pletion with results from the National Immunization 
Survey (NIS) is useful. For 2008, IISAR data indi-
cated that 47% of children participating in an IIS 
had complete histories for the full 4:3:1:3:3:1 series. 
This is lower than the estimated proportion (76%) of 
children reported by NIS to have received the same 
series (6). 
The findings in this report are subject to at least 
two limitations. First, data from the 2008 IISAR were 
not validated by independent review. Second, because 
some grantees did not report data, the nationwide 
IIS participation rates for children aged <6 years and 
providers might be underestimated. 
An additional CDC initiative is to implement 
national standards to enhance the interoperability of 
electronic data exchanges between electronic health 
record systems in immunization provider offices and 
IISs. Enhanced interoperability will improve the com-
pleteness of immunization histories available to clini-
cians and public health practitioners, the timeliness 
of immunization data submission to IISs, the quality 
of IIS coverage assessments, and the data available to 
other public health systems (e.g., vaccine-preventable 
disease surveillance units).
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TABLE. Percentage of core data elements* that were complete† in immunization information system (IIS) records for children 
aged <6 years — United States, 2006 and 2008
Core data element 2006 (N = 51) (%) 2008 (N = 52) (%) Change (%)
First name 100 100 0
Middle name 67 68 +1
Last name 100 100 0
Birth date 100 100 0
Sex 96 97 +1
Birth state 54 44 -10
Birth country 18 28 +10
Mother’s first name 71 67 -4
Mother’s maiden name 55 50 -5
Mother’s last name 66 59 -7
Vaccine type 99 98 -1
Vaccine manufacture 37 40 +3
Vaccination date 99 98 -1
Vaccine lot number 37 38 +1
Race§ 60 59 -1
Ethnicity§ 42 39 -3
Patient birth order —¶ 63 —
* Recommended by the National Vaccine Advisory Committee. Additional information available at http://www.cdc.gov/vaccines/programs/
iis/stds/coredata.htm.
† Calculated by number of data field completions in IIS records and the overall number of IIS records.
§ Additional required core data elements as recommended by the National Vaccine Advisory Committee in 2007.
¶ Not available.
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In the report, “Racial/Ethnic Disparities Among 
Children with Diagnoses of Perinatal HIV Infection 
— 34 States, 2004–2007,” errors occurred in the fifth 
sentence on page 97. The sentence should read, “The 
average annual rate of diagnoses of perinatal HIV 
infection during 2004–2007 was 12.3 per 100,000 
among black infants (69%), 2.0 per 100,000 among 
Hispanic infants, and 0.5 per 100,000 among white 
infants.” Errors also occurred in the table on page 
99. Under the 95% confidence intervals for the rates 
for Blacks/African Americans, Hispanics, and Other/
Multiple, the lower confidence limits should be 11.1, 
1.6, and 1.1, respectively. Under the 95% confidence 
intervals for the rate ratio for Other/Multiple, the 
lower confidence limit should be 2.0. 
Errata Vol. 59, No. 4
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TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending 









Total cases reported 
for previous years States reporting cases 
during current week (No.)2009 2008 2007 2006 2005
Anthrax — — — — — 1 1 —
Botulism, total — 4 2 98 145 144 165 135
 foodborne — — 0 11 17 32 20 19
 infant — 4 2 64 109 85 97 85
 other (wound and unspecified) — — 0 23 19 27 48 31
Brucellosis 1 3 1 108 80 131 121 120 FL (1)
Chancroid — 11 1 46 25 23 33 17
Cholera — — 0 8 5 7 9 8
Cyclosporiasis§ 1 3 2 127 139 93 137 543 FL (1)
Diphtheria — — — — — — — —
Domestic arboviral diseases § ,¶:
 California serogroup virus disease — — 0 43 62 55 67 80
 Eastern equine encephalitis virus disease — — — 4 4 4 8 21
 Powassan virus disease — — — 1 2 7 1 1
 St. Louis encephalitis virus disease — — 0 11 13 9 10 13
 Western equine encephalitis virus disease — — — — — — — —
Haemophilus influenzae,** invasive disease (age <5 yrs):
 serotype b 1 1 1 26 30 22 29 9 CO (1)
 nonserotype b — 14 4 215 244 199 175 135
 unknown serotype 3 27 5 230 163 180 179 217 NYC (1), GA (1), FL (1)
Hansen disease§ — 6 2 59 80 101 66 87
Hantavirus pulmonary syndrome§ — 1 0 13 18 32 40 26
Hemolytic uremic syndrome, postdiarrheal§ 1 5 2 225 330 292 288 221 FL (1)
HIV infection, pediatric (age <13 yrs)†† — — 2 — — — — 380
Influenza-associated pediatric mortality§,§§ 3 33 2 360 90 77 43 45 PA (1), GA (1), NM (1)
Listeriosis 3 29 9 780 759 808 884 896 PA (2), AZ (1)
Measles¶¶ — 1 1 63 140 43 55 66
Meningococcal disease, invasive***:
 A, C, Y, and W-135 3 12 7 282 330 325 318 297 OH (1), FL (1), OK (1)
 serogroup B — 5 4 148 188 167 193 156
 other serogroup — — 1 23 38 35 32 27
 unknown serogroup 6 41 13 477 616 550 651 765 DE (1), FL (2), AR (1), OR (1), CA (1)
Mumps 68 253 11 1,316 454 800 6,584 314 NY (65), MI (1), MD (1), WV (1)
Novel influenza A virus infections††† — — 0 43,771 2 4 NN NN
Plague — — — 8 3 7 17 8
Poliomyelitis, paralytic — — — — — — — 1
Polio virus Infection, nonparalytic§ — — — — — — NN NN
Psittacosis§ — 1 0 9 8 12 21 16
Q fever, total§,§§§ 1 1 1 99 120 171 169 136
 acute 1 1 1 83 106 — — — FL (1)
 chronic — — 0 16 14 — — —
Rabies, human — — 0 4 2 1 3 2
Rubella¶¶¶ — 1 0 3 16 12 11 11
Rubella, congenital syndrome — — 0 1 — — 1 1
SARS-CoV§,**** — — — — — — — —
Smallpox§ — — — — — — — —
Streptococcal toxic-shock syndrome§ 1 5 3 131 157 132 125 129 NY (1)
Syphilis, congenital (age <1 yr) — 2 7 266 431 430 349 329
Tetanus — — 0 16 19 28 41 27
Toxic-shock syndrome (staphylococcal)§ 3 8 1 75 71 92 101 90 PA (1), CA (2)
Trichinellosis — — 0 12 39 5 15 16
Tularemia — — 0 86 123 137 95 154
Typhoid fever 5 23 7 341 449 434 353 324 NY (1), OH (1), MO (1), FL (1), CA (1)
Vancomycin-intermediate Staphylococcus aureus§ 2 4 0 71 63 37 6 2 NY (1), MO (1)
Vancomycin-resistant Staphylococcus aureus§ — — — — — 2 1 3
Vibriosis (noncholera Vibrio species infections)§ 2 7 1 659 588 549 NN NN FL (1), CA (1)
Viral Hemorrhagic Fever†††† — — — NN NN NN NN NN
Yellow fever — — — — — — — —
See Table I footnotes on next page.
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Notifiable Disease Data Team and 122 Cities Mortality Data Team
 Patsy A. Hall-Baker
Deborah A. Adams  Rosaline Dhara
Willie J. Anderson  Pearl C. Sharp
Jose Aponte  Michael S. Wodajo
Lenee Blanton
* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the 
past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week 
totals.
FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week 
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TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending 
February 6, 2010 (5th week)*
—: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts.
 * Incidence data for reporting years 2009 and 2010 are provisional, whereas data for 2005 through 2008 are finalized.
 † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. 
Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
 § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
 ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and 
Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
 ** Data for H. influenzae (all ages, all serotypes) are available in Table II.
 †† Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences 
the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is 
completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
 §§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Since April 26, 2009, a total of 274 influenza-associated pediatric 
deaths associated with 2009 influenza A (H1N1) virus infection have been reported. Since August 30, 2009, a total of 260 influenza-associated pediatric deaths occurring during the 
2009–10 influenza season have been reported. A total of 132 influenza-associated pediatric deaths occurring during the 2008-09 influenza season have been reported.
 ¶¶ No measles cases were reported for the current week.
 *** Data for meningococcal disease (all serogroups) are available in Table II.
 ††† CDC discontinued reporting of individual confirmed and probable cases of 2009 pandemic influenza A (H1N1) virus infections on July 24, 2009. CDC will report the total number of 2009 
pandemic influenza A (H1N1) hospitalizations and deaths weekly on the CDC H1N1 influenza website (http://www.cdc.gov/h1n1flu). In addition, three cases of novel influenza A virus 
infections, unrelated to the 2009 pandemic influenza A (H1N1) virus, were reported to CDC during 2009.
 §§§ In 2009, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with 
respect to acute and chronic Q fever cases.
 ¶¶¶ No rubella cases were reported for the current week.
 **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.
 †††† There were no cases of Viral Hemorrhagic Fever during week one. See Table II for Dengue Hemorrhagic Fever.
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TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending February 6, 2010, and February 7, 2009 (5th week)*
Reporting area
Chlamydia trachomatis infection Cryptosporidiosis
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 9,713 23,266 27,448 72,855 119,138 77 113 261 346 412
New England 445 760 1,482 2,480 3,659 1 6 23 17 59
Connecticut — 225 531 81 682 — 0 3 3 38
Maine† — 47 75 184 290 1 1 4 7 3
Massachusetts 444 377 944 1,872 2,109 — 2 16 — 11
New Hampshire 1 33 50 20 232 — 1 5 2 6
Rhode Island† — 63 244 232 268 — 0 8 — 1
Vermont† — 23 63 91 78 — 1 9 5 —
Mid. Atlantic 2,820 3,004 4,299 14,140 14,632 5 14 37 40 45
New Jersey 270 410 630 1,237 2,591 — 0 5 — 4
New York (Upstate) 609 606 1,846 2,363 2,087 3 3 16 7 15
New York City 1,290 1,171 1,956 6,639 5,872 — 1 5 2 11
Pennsylvania 651 820 988 3,901 4,082 2 9 19 31 15
E.N. Central 1,148 3,361 4,281 8,401 19,977 10 26 54 83 99
Illinois — 1,038 1,219 137 6,519 — 3 8 7 14
Indiana — 410 694 685 2,036 — 4 9 — 18
Michigan 873 870 1,332 4,443 4,628 4 5 11 25 19
Ohio 93 474 1,025 1,709 4,898 4 7 16 27 24
Wisconsin 182 391 480 1,427 1,896 2 8 24 24 24
W.N. Central 541 1,317 1,699 4,194 6,555 5 18 61 27 35
Iowa 6 173 252 211 1,011 2 3 14 8 6
Kansas 24 185 561 686 746 — 2 6 5 4
Minnesota 3 259 338 412 1,444 — 4 34 1 8
Missouri 433 508 638 2,352 2,419 2 3 12 8 8
Nebraska† 75 108 236 520 494 1 2 9 5 5
North Dakota — 31 92 13 127 — 0 5 — —
South Dakota — 51 80 — 314 — 1 10 — 4
S. Atlantic 1,698 4,667 6,206 13,070 22,037 44 17 45 85 98
Delaware 71 87 180 402 517 — 0 2 1 —
District of Columbia 90 123 225 472 722 — 0 1 — 1
Florida 625 1,419 1,671 5,361 6,921 15 7 24 35 32
Georgia 13 699 1,150 38 2,794 29 5 23 45 40
Maryland† — 443 958 1,081 1,647 — 0 5 — 4
North Carolina — 711 1,265 — 4,179 — 0 8 — 14
South Carolina† 587 523 1,421 2,623 2,467 — 1 7 2 1
Virginia† 254 602 926 2,773 2,406 — 1 7 1 5
West Virginia 58 69 136 320 384 — 0 2 1 1
E.S. Central 474 1,735 2,220 5,098 8,471 2 4 10 11 10
Alabama† — 465 629 807 2,224 1 1 5 1 3
Kentucky — 241 642 736 1,172 1 1 4 6 1
Mississippi — 429 840 971 2,146 — 0 3 — 3
Tennessee† 474 580 808 2,584 2,929 — 1 5 4 3
W.S. Central 1,024 3,057 5,800 13,182 15,941 3 8 36 10 11
Arkansas† 331 269 416 1,185 1,455 3 1 5 4 1
Louisiana 227 523 928 1,924 3,529 — 0 6 — —
Oklahoma 388 179 2,714 2,165 706 — 2 9 1 2
Texas† 78 2,020 2,684 7,908 10,251 — 5 21 5 8
Mountain 407 1,398 2,096 2,278 6,702 5 9 26 43 25
Arizona 56 493 755 479 2,127 — 0 3 2 4
Colorado — 266 689 — 1,846 2 2 10 14 6
Idaho† — 64 184 127 324 2 1 7 10 2
Montana† 30 55 86 229 333 1 1 4 6 2
Nevada† 83 175 478 821 892 — 0 2 1 —
New Mexico† 221 175 344 335 351 — 2 8 4 9
Utah 17 111 160 287 659 — 0 4 4 —
Wyoming† — 34 69 — 170 — 0 2 2 2
Pacific 1,156 3,542 4,453 10,012 21,164 2 14 24 30 30
Alaska — 98 128 391 584 — 0 1 1 1
California 564 2,680 3,475 6,910 16,697 — 8 20 14 17
Hawaii — 119 147 272 572 — 0 1 — —
Oregon 306 217 468 1,035 858 1 3 10 10 10
Washington 286 393 571 1,404 2,453 1 1 7 5 2
American Samoa — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam — 0 0 — — — 0 0 — —
Puerto Rico 170 130 331 530 657 N 0 0 N N
U.S. Virgin Islands — 10 17 — 22 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 6, 2010, and February 7, 2009 (5th week)*
Dengue Virus Infection
Reporting area
Dengue Fever Dengue Hemorrhagic Fever†
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States — 0 0 — NN — 0 0 — NN
New England — 0 0 — NN — 0 0 — NN
Connecticut — 0 0 — NN — 0 0 — NN
Maine§ — 0 0 — NN — 0 0 — NN
Massachusetts — 0 0 — NN — 0 0 — NN
New Hampshire — 0 0 — NN — 0 0 — NN
Rhode Island§ — 0 0 — NN — 0 0 — NN
Vermont§ — 0 0 — NN — 0 0 — NN
Mid. Atlantic — 0 0 — NN — 0 0 — NN
New Jersey — 0 0 — NN — 0 0 — NN
New York (Upstate) — 0 0 — NN — 0 0 — NN
New York City — 0 0 — NN — 0 0 — NN
Pennsylvania — 0 0 — NN — 0 0 — NN
E.N. Central — 0 0 — NN — 0 0 — NN
Illinois — 0 0 — NN — 0 0 — NN
Indiana — 0 0 — NN — 0 0 — NN
Michigan — 0 0 — NN — 0 0 — NN
Ohio — 0 0 — NN — 0 0 — NN
Wisconsin — 0 0 — NN — 0 0 — NN
W.N. Central — 0 0 — NN — 0 0 — NN
Iowa — 0 0 — NN — 0 0 — NN
Kansas — 0 0 — NN — 0 0 — NN
Minnesota — 0 0 — NN — 0 0 — NN
Missouri — 0 0 — NN — 0 0 — NN
Nebraska§ — 0 0 — NN — 0 0 — NN
North Dakota — 0 0 — NN — 0 0 — NN
South Dakota — 0 0 — NN — 0 0 — NN
S. Atlantic — 0 0 — NN — 0 0 — NN
Delaware — 0 0 — NN — 0 0 — NN
District of Columbia — 0 0 — NN — 0 0 — NN
Florida — 0 0 — NN — 0 0 — NN
Georgia — 0 0 — NN — 0 0 — NN
Maryland§ — 0 0 — NN — 0 0 — NN
North Carolina — 0 0 — NN — 0 0 — NN
South Carolina§ — 0 0 — NN — 0 0 — NN
Virginia§ — 0 0 — NN — 0 0 — NN
West Virginia — 0 0 — NN — 0 0 — NN
E.S. Central — 0 0 — NN — 0 0 — NN
Alabama§ — 0 0 — NN — 0 0 — NN
Kentucky — 0 0 — NN — 0 0 — NN
Mississippi — 0 0 — NN — 0 0 — NN
Tennessee§ — 0 0 — NN — 0 0 — NN
W.S. Central — 0 0 — NN — 0 0 — NN
Arkansas§ — 0 0 — NN — 0 0 — NN
Louisiana — 0 0 — NN — 0 0 — NN
Oklahoma — 0 0 — NN — 0 0 — NN
Texas§ — 0 0 — NN — 0 0 — NN
Mountain — 0 0 — NN — 0 0 — NN
Arizona — 0 0 — NN — 0 0 — NN
Colorado — 0 0 — NN — 0 0 — NN
Idaho§ — 0 0 — NN — 0 0 — NN
Montana§ — 0 0 — NN — 0 0 — NN
Nevada§ — 0 0 — NN — 0 0 — NN
New Mexico§ — 0 0 — NN — 0 0 — NN
Utah — 0 0 — NN — 0 0 — NN
Wyoming§ — 0 0 — NN — 0 0 — NN
Pacific — 0 0 — NN — 0 0 — NN
Alaska — 0 0 — NN — 0 0 — NN
California — 0 0 — NN — 0 0 — NN
Hawaii — 0 0 — NN — 0 0 — NN
Oregon — 0 0 — NN — 0 0 — NN
Washington — 0 0 — NN — 0 0 — NN
American Samoa — 0 0 — NN — 0 0 — NN
C.N.M.I. — — — — NN — — — — NN
Guam — 0 0 — NN — 0 0 — NN
Puerto Rico — 0 0 — NN — 0 0 — NN
U.S. Virgin Islands — 0 0 — NN — 0 0 — NN
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† DHF includes cases that meet criteria for dengue shock syndrome (DSS), a more severe form of DHF.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 6, 2010, and February 7, 2009 (5th week)*
Ehrlichiosis/Anaplasmosis†
Reporting area
Ehrlichia chaffeensis Anaplasma phagocytophilum Undetermined
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 1 11 64 8 10 — 13 52 2 4 1 2 13 1 1
New England — 0 4 — — — 1 21 1 1 — 0 2 — —
Connecticut — 0 0 — — — 0 1 — — — 0 0 — —
Maine§ — 0 1 — — — 0 3 1 — — 0 0 — —
Massachusetts — 0 0 — — — 0 0 — — — 0 0 — —
New Hampshire — 0 1 — — — 0 3 — 1 — 0 1 — —
Rhode Island§ — 0 4 — — — 0 20 — — — 0 1 — —
Vermont§ — 0 1 — — — 0 0 — — — 0 0 — —
Mid. Atlantic — 2 14 — — — 3 21 — — — 0 2 — —
New Jersey — 0 1 — — — 0 0 — — — 0 0 — —
New York (Upstate) — 1 14 — — — 3 20 — — — 0 1 — —
New York City — 0 3 — — — 0 1 — — — 0 2 — —
Pennsylvania — 0 1 — — — 0 0 — — — 0 0 — —
E.N. Central — 1 8 — — — 3 22 — — — 1 9 — —
Illinois — 0 4 — — — 0 1 — — — 0 1 — —
Indiana — 0 0 — — — 0 0 — — — 0 8 — —
Michigan — 0 0 — — — 0 0 — — — 0 0 — —
Ohio — 0 2 — — — 0 1 — — — 0 1 — —
Wisconsin — 0 5 — — — 3 22 — — — 0 3 — —
W.N. Central — 2 24 — — — 0 32 — — 1 0 5 1 —
Iowa — 0 0 — — — 0 0 — — — 0 0 — —
Kansas — 0 2 — — — 0 0 — — — 0 0 — —
Minnesota — 0 3 — — — 0 32 — — — 0 5 — —
Missouri — 1 22 — — — 0 1 — — 1 0 3 1 —
Nebraska§ — 0 2 — — — 0 1 — — — 0 0 — —
North Dakota — 0 0 — — — 0 0 — — — 0 0 — —
South Dakota — 0 0 — — — 0 0 — — — 0 0 — —
S. Atlantic 1 3 24 8 8 — 0 2 1 2 — 0 2 — —
Delaware — 0 2 1 — — 0 1 — — — 0 0 — —
District of Columbia — 0 0 — — — 0 0 — — — 0 0 — —
Florida — 0 1 1 1 — 0 1 — — — 0 0 — —
Georgia 1 0 2 2 — — 0 1 1 — — 0 0 — —
Maryland§ — 1 4 4 4 — 0 1 — 1 — 0 1 — —
North Carolina — 0 4 — 3 — 0 1 — 1 — 0 0 — —
South Carolina§ — 0 1 — — — 0 0 — — — 0 0 — —
Virginia§ — 0 14 — — — 0 1 — — — 0 2 — —
West Virginia — 0 1 — — — 0 0 — — — 0 0 — —
E.S. Central — 1 11 — 2 — 0 1 — 1 — 0 6 — 1
Alabama§ — 0 3 — — — 0 1 — — — 0 0 — —
Kentucky — 0 2 — — — 0 0 — — — 0 1 — —
Mississippi — 0 0 — — — 0 0 — — — 0 0 — —
Tennessee§ — 1 11 — 2 — 0 1 — 1 — 0 6 — 1
W.S. Central — 0 9 — — — 0 1 — — — 0 0 — —
Arkansas§ — 0 5 — — — 0 0 — — — 0 0 — —
Louisiana — 0 0 — — — 0 0 — — — 0 0 — —
Oklahoma — 0 8 — — — 0 1 — — — 0 0 — —
Texas§ — 0 1 — — — 0 1 — — — 0 0 — —
Mountain — 0 0 — — — 0 0 — — — 0 1 — —
Arizona — 0 0 — — — 0 0 — — — 0 1 — —
Colorado — 0 0 — — — 0 0 — — — 0 0 — —
Idaho§ — 0 0 — — — 0 0 — — — 0 0 — —
Montana§ — 0 0 — — — 0 0 — — — 0 0 — —
Nevada§ — 0 0 — — — 0 0 — — — 0 0 — —
New Mexico§ — 0 0 — — — 0 0 — — — 0 0 — —
Utah — 0 0 — — — 0 0 — — — 0 0 — —
Wyoming§ — 0 0 — — — 0 0 — — — 0 0 — —
Pacific — 0 1 — — — 0 0 — — — 0 0 — —
Alaska — 0 0 — — — 0 0 — — — 0 0 — —
California — 0 1 — — — 0 0 — — — 0 0 — —
Hawaii — 0 0 — — — 0 0 — — — 0 0 — —
Oregon — 0 0 — — — 0 0 — — — 0 0 — —
Washington — 0 0 — — — 0 0 — — — 0 0 — —
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Cumulative total E. ewingii cases reported as of this week = 0.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 6, 2010, and February 7, 2009 (5th week)*
Reporting area
Giardiasis Gonorrhea
Haemophilus influenzae, invasive†  
All ages, all serotypes
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 191 331 509 1,004 1,387 2,254 5,553 6,890 18,040 30,084 35 55 121 225 355
New England 2 30 64 37 105 67 96 210 336 468 — 3 12 3 14
Connecticut — 5 15 6 25 — 47 106 48 160 — 0 9 — —
Maine§ 1 4 13 14 13 — 3 11 25 9 — 0 2 — 2
Massachusetts — 13 36 — 42 65 38 112 220 256 — 2 8 — 9
New Hampshire — 3 11 6 8 2 2 6 16 11 — 0 2 3 3
Rhode Island§ — 1 6 — 6 — 6 19 23 30 — 0 2 — —
Vermont§ 1 3 14 11 11 — 1 5 4 2 — 0 1 — —
Mid. Atlantic 40 61 100 178 260 551 590 840 3,024 3,024 12 12 25 63 62
New Jersey — 2 12 — 47 57 88 124 363 473 — 2 7 4 9
New York (Upstate) 32 25 56 87 75 101 102 296 385 437 4 3 17 17 18
New York City 2 15 26 37 83 252 213 371 1,327 1,106 1 2 11 9 5
Pennsylvania 6 15 35 54 55 141 194 275 949 1,008 7 4 10 33 30
E.N. Central 29 44 74 154 212 278 1,043 1,352 2,414 6,391 3 11 29 27 96
Illinois — 10 21 17 52 — 335 382 47 2,032 — 3 9 5 23
Indiana N 0 0 N N — 130 209 227 737 — 1 5 — 8
Michigan 7 11 24 34 48 206 261 501 1,384 1,676 — 0 3 — 2
Ohio 18 15 28 78 72 34 160 333 457 1,447 3 2 6 18 16
Wisconsin 4 9 19 25 40 38 94 146 299 499 — 4 21 4 47
W.N. Central 13 25 145 98 116 104 273 358 895 1,568 2 2 20 12 20
Iowa 2 6 15 25 27 2 32 47 37 167 — 0 0 — —
Kansas 1 3 14 20 13 3 43 84 110 235 — 0 2 2 2
Minnesota — 0 124 — — 1 40 65 57 250 — 0 16 — 4
Missouri 6 9 27 34 46 85 123 172 580 720 — 1 6 7 8
Nebraska§ 4 3 9 17 20 13 23 55 110 136 — 0 4 1 5
North Dakota — 0 8 — — — 2 14 1 7 2 0 2 2 1
South Dakota — 0 5 2 10 — 4 14 — 53 — 0 0 — —
S. Atlantic 40 70 109 232 338 539 1,352 1,784 3,891 6,826 9 13 31 51 86
Delaware 1 0 3 3 3 28 18 37 92 100 — 0 1 — —
District of Columbia — 0 5 — 10 27 48 88 175 315 — 0 1 — —
Florida 30 37 59 152 176 187 409 476 1,613 2,073 3 4 10 15 27
Georgia 5 10 67 15 83 10 239 465 19 942 4 3 8 21 19
Maryland§ 2 5 13 20 25 — 119 225 329 495 1 1 6 3 10
North Carolina N 0 0 N N — 236 377 — 1,470 — 0 17 — 9
South Carolina§ — 2 8 9 7 173 159 412 805 756 — 1 7 11 6
Virginia§ 1 8 20 29 32 112 153 272 819 598 — 1 5 — 9
West Virginia 1 1 5 4 2 2 9 18 39 77 1 0 3 1 6
E.S. Central 3 8 22 19 30 142 472 649 1,537 2,661 1 3 12 11 20
Alabama§ 1 4 13 9 18 — 133 186 294 708 — 1 4 — 4
Kentucky N 0 0 N N — 60 156 208 372 — 0 5 1 1
Mississippi N 0 0 N N — 132 252 299 691 — 0 1 — 2
Tennessee§ 2 4 18 10 12 142 153 220 736 890 1 2 10 10 13
W.S. Central 8 7 19 23 25 311 893 1,555 3,709 4,826 2 2 7 5 10
Arkansas§ 5 3 9 12 5 130 86 139 374 430 — 0 3 — 2
Louisiana — 1 7 — 16 59 166 299 603 1,198 — 0 1 — 3
Oklahoma 3 3 10 11 4 104 61 613 575 229 2 1 5 5 5
Texas§ N 0 0 N N 18 560 757 2,157 2,969 — 0 2 — —
Mountain 23 26 61 107 128 70 170 238 309 886 5 5 13 44 37
Arizona — 4 7 12 19 18 58 91 75 271 1 2 9 17 18
Colorado 20 8 26 53 37 — 39 106 — 340 3 1 6 12 8
Idaho§ 2 3 10 14 12 — 2 8 5 14 — 0 1 2 1
Montana§ — 2 11 6 14 1 1 5 7 7 — 0 1 — 1
Nevada§ 1 1 10 4 2 15 28 94 162 129 1 0 2 3 1
New Mexico§ — 1 8 — 10 36 21 34 56 78 — 0 4 5 3
Utah — 5 13 11 27 — 5 13 4 39 — 1 2 1 5
Wyoming§ — 1 5 7 7 — 1 7 — 8 — 0 2 4 —
Pacific 33 51 110 156 173 192 540 693 1,925 3,434 1 2 8 9 10
Alaska — 2 7 6 4 — 19 32 81 92 — 0 3 3 2
California 24 35 61 102 130 139 442 567 1,553 2,892 — 0 4 — 2
Hawaii — 0 2 — 2 — 12 24 40 52 — 0 3 — 4
Oregon 2 7 18 30 24 19 20 44 84 115 1 1 4 4 2
Washington 7 7 61 18 13 34 41 71 167 283 — 0 4 2 —
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 1 10 1 11 7 4 24 19 18 — 0 1 — —
U.S. Virgin Islands — 0 0 — — — 2 7 — 7 N 0 0 N N
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Data for H. influenzae (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 6, 2010, and February 7, 2009 (5th week)*

















Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 26 36 57 94 180 25 62 89 155 333 9 17 39 40 77
New England 2 2 5 5 9 1 1 3 2 6 — 1 5 1 8
Connecticut 2 0 2 5 1 — 0 3 1 3 — 0 4 1 5
Maine† — 0 1 — 1 1 0 2 1 — — 0 2 — —
Massachusetts — 1 4 — 6 — 0 2 — 3 — 0 1 — 2
New Hampshire — 0 1 — 1 — 0 1 — — — 0 0 — —
Rhode Island† — 0 1 — — — 0 0 — — — 0 0 — —
Vermont† — 0 1 — — — 0 0 — — — 0 0 — 1
Mid. Atlantic 2 5 10 12 27 2 5 16 11 29 2 2 7 5 11
New Jersey — 1 5 2 8 — 1 6 — 6 — 0 1 — 1
New York (Upstate) 2 1 3 3 6 1 1 7 4 10 2 1 4 5 2
New York City — 2 5 4 7 — 1 5 1 3 — 0 0 — —
Pennsylvania — 1 6 3 6 1 2 8 6 10 — 0 4 — 8
E.N. Central 1 5 19 15 34 2 6 15 16 63 1 3 14 8 20
Illinois — 2 13 — 14 — 1 7 — 11 — 0 1 — 3
Indiana — 0 4 — 3 — 1 5 1 10 — 0 4 — 2
Michigan — 1 4 6 9 — 2 6 5 12 1 3 12 8 10
Ohio 1 0 4 7 7 2 1 5 10 25 — 0 5 — 4
Wisconsin — 0 4 2 1 — 0 4 — 5 — 0 2 — 1
W.N. Central — 2 7 3 5 2 3 8 9 20 — 0 4 2 1
Iowa — 0 3 2 — — 0 3 1 6 — 0 4 — —
Kansas — 0 2 — — — 0 2 — 1 — 0 1 — —
Minnesota — 0 4 — 1 — 0 7 — 1 — 0 2 — —
Missouri — 0 3 1 4 1 1 5 6 8 — 0 2 2 1
Nebraska† — 0 3 — — 1 0 2 2 3 — 0 1 — —
North Dakota — 0 1 — — — 0 0 — — — 0 1 — —
South Dakota — 0 1 — — — 0 1 — 1 — 0 0 — —
S. Atlantic 4 8 14 17 43 8 16 32 59 93 3 3 12 6 9
Delaware — 0 1 — — U 0 0 U U U 0 0 U U
District of Columbia U 0 0 U U U 0 0 U U U 0 0 U U
Florida 4 3 9 8 23 4 6 13 30 32 3 1 4 4 1
Georgia — 1 3 2 7 — 3 7 16 22 — 0 3 — 2
Maryland† — 0 3 1 7 2 1 5 3 12 — 0 3 2 2
North Carolina — 0 7 — 4 2 0 19 2 18 — 0 10 — —
South Carolina† — 1 4 5 1 — 1 4 — — — 0 1 — —
Virginia† — 1 3 1 1 — 1 6 6 6 — 0 2 — 1
West Virginia — 0 2 — — — 0 19 2 3 — 0 2 — 3
E.S. Central 1 1 3 4 5 1 7 13 30 42 2 1 5 8 14
Alabama† — 0 2 2 1 — 1 5 7 14 — 0 2 — —
Kentucky 1 0 2 1 — — 2 6 13 9 1 1 5 7 9
Mississippi — 0 1 — 3 — 0 2 — 4 — 0 0 — —
Tennessee† — 0 2 1 1 1 3 6 10 15 1 0 3 1 5
W.S. Central — 3 12 5 10 2 9 18 9 36 — 1 6 2 3
Arkansas† — 0 1 — 1 — 1 4 — 3 — 0 1 — —
Louisiana — 0 1 — 1 — 0 4 — 6 — 0 1 — —
Oklahoma — 0 3 — 1 — 2 8 1 4 — 0 4 — —
Texas† — 3 12 5 7 2 6 12 8 23 — 0 4 2 3
Mountain 3 3 8 14 12 — 2 6 5 18 — 1 4 1 6
Arizona 2 1 5 10 7 — 0 3 1 7 — 0 0 — —
Colorado 1 1 5 3 2 — 0 2 — 5 — 0 3 — 4
Idaho† — 0 1 1 — — 0 2 — — — 0 1 — —
Montana† — 0 1 — — — 0 0 — — — 0 0 — —
Nevada† — 0 2 — — — 0 3 4 1 — 0 1 — —
New Mexico† — 0 1 — 1 — 0 1 — 3 — 0 2 — 2
Utah — 0 2 — 2 — 0 1 — 2 — 0 2 1 —
Wyoming† — 0 1 — — — 0 2 — — — 0 0 — —
Pacific 13 5 17 19 35 7 5 17 14 26 1 1 5 7 5
Alaska — 0 1 — 1 — 0 1 1 — — 0 2 — —
California 12 5 16 16 29 7 4 10 12 21 — 1 4 3 2
Hawaii — 0 2 — 1 — 0 1 — — — 0 0 — —
Oregon — 0 2 2 2 — 1 4 1 3 — 0 3 3 2
Washington 1 1 3 1 2 — 0 7 — 2 1 0 3 1 1
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 2 1 2 — 0 5 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 6, 2010, and February 7, 2009 (5th week)*
Reporting area
Legionellosis Lyme disease Malaria
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 17 55 163 151 175 58 350 1,984 447 750 12 22 48 73 103
New England 1 3 18 4 7 4 66 486 11 125 — 1 4 — 7
Connecticut 1 1 5 3 3 — 0 0 — — — 0 3 — —
Maine† — 0 3 — — 4 11 76 6 4 — 0 1 — —
Massachusetts — 1 9 — 4 — 29 327 — 72 — 0 3 — 6
New Hampshire — 0 2 1 — — 14 89 — 33 — 0 1 — —
Rhode Island† — 0 4 — — — 1 28 — — — 0 1 — —
Vermont† — 0 1 — — — 5 42 5 16 — 0 1 — 1
Mid. Atlantic 8 15 69 37 44 25 186 1,097 224 316 3 6 13 24 16
New Jersey — 2 13 — 5 — 38 378 14 134 — 0 1 — —
New York (Upstate) 5 5 29 16 14 12 53 283 48 36 3 1 4 8 5
New York City — 3 20 7 2 — 2 25 — 7 — 4 11 10 8
Pennsylvania 3 6 25 14 23 13 95 637 162 139 — 1 4 6 3
E.N. Central 1 10 38 23 41 2 23 223 24 46 — 2 10 2 13
Illinois — 1 10 1 1 — 1 11 — 1 — 1 5 — 4
Indiana — 1 4 1 5 — 1 7 1 — — 0 3 — 3
Michigan — 2 11 4 9 — 1 10 2 — — 0 3 1 2
Ohio 1 4 17 16 22 — 1 5 1 2 — 0 6 1 4
Wisconsin — 1 5 1 4 2 20 205 20 43 — 0 1 — —
W.N. Central 1 2 10 2 2 — 5 76 — 5 — 1 8 7 5
Iowa — 0 2 — 1 — 1 14 — 2 — 0 1 1 2
Kansas — 0 1 — 1 — 0 2 — 2 — 0 1 1 1
Minnesota — 0 9 — — — 0 76 — — — 0 8 — 1
Missouri — 1 5 1 — — 0 1 — — — 0 2 2 1
Nebraska† 1 0 2 1 — — 0 3 — — — 0 2 3 —
North Dakota — 0 1 — — — 0 0 — — — 0 1 — —
South Dakota — 0 1 — — — 0 0 — 1 — 0 1 — —
S. Atlantic 4 10 21 36 46 26 62 238 169 239 6 6 17 30 39
Delaware — 0 5 3 — 6 13 65 45 42 — 0 1 — 1
District of Columbia — 0 2 — 1 — 0 5 — 1 — 0 2 — 2
Florida 4 4 10 18 15 1 2 11 8 5 3 2 7 16 9
Georgia — 1 4 3 12 — 1 6 1 1 — 1 5 2 4
Maryland† — 3 12 7 7 18 26 126 81 166 3 1 13 8 10
North Carolina — 0 5 — 11 — 0 14 — 5 — 0 5 — 8
South Carolina† — 0 2 — — — 0 3 1 2 — 0 1 — 1
Virginia† — 1 5 4 — — 10 52 31 17 — 1 5 4 4
West Virginia — 0 2 1 — 1 0 33 2 — — 0 1 — —
E.S. Central — 2 12 9 11 — 1 4 6 2 1 0 3 3 5
Alabama† — 0 2 — 2 — 0 1 — — — 0 3 1 1
Kentucky — 1 3 3 2 — 0 1 1 — 1 0 3 2 —
Mississippi — 0 2 — — — 0 0 — — — 0 1 — —
Tennessee† — 1 9 6 7 — 1 4 5 2 — 0 2 — 4
W.S. Central — 2 7 4 1 — 2 10 — — 1 1 10 1 3
Arkansas† — 0 1 — — — 0 0 — — — 0 1 — —
Louisiana — 0 2 — 1 — 0 0 — — — 0 1 — 1
Oklahoma — 0 2 — — — 0 0 — — 1 0 1 1 —
Texas† — 2 6 4 — — 2 10 — — — 1 9 — 2
Mountain 1 3 8 9 12 — 1 4 4 2 — 0 6 1 3
Arizona 1 1 4 5 4 — 0 2 1 — — 0 2 1 —
Colorado — 0 4 2 — — 0 1 1 — — 0 3 — 1
Idaho† — 0 2 — 1 — 0 3 1 1 — 0 1 — —
Montana† — 0 2 — 2 — 0 1 — — — 0 3 — —
Nevada† — 0 1 2 3 — 0 1 — — — 0 0 — —
New Mexico† — 0 2 — — — 0 1 — — — 0 0 — —
Utah — 0 4 — 2 — 0 1 1 1 — 0 1 — 2
Wyoming† — 0 2 — — — 0 1 — — — 0 0 — —
Pacific 1 3 19 27 11 1 4 11 9 15 1 3 13 5 12
Alaska — 0 1 — — — 0 1 — 1 — 0 1 — —
California 1 3 19 27 8 — 3 10 5 13 — 2 8 3 10
Hawaii — 0 1 — 1 N 0 0 N N — 0 1 — —
Oregon — 0 2 — 1 1 1 4 4 1 — 0 2 — 1
Washington — 0 4 — 1 — 0 3 — — 1 0 4 2 1
American Samoa N 0 0 N N N 0 0 N N — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 1 — — N 0 0 N N — 0 1 — 1
U.S. Virgin Islands — 0 0 — — N 0 0 N N — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 6, 2010, and February 7, 2009 (5th week)*
Reporting area
Meningococcal disease, invasive† 
All groups Pertussis Rabies, animal
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 9 16 33 58 75 58 269 849 480 1,214 15 62 140 132 421
New England — 0 4 — 5 — 11 24 2 80 4 6 24 18 21
Connecticut — 0 2 — — — 1 4 — 4 3 1 22 5 8
Maine§ — 0 1 — — — 1 10 — 16 — 1 4 6 3
Massachusetts — 0 3 — 4 — 6 16 — 48 — 0 0 — —
New Hampshire — 0 1 — 1 — 1 7 1 7 — 0 3 2 2
Rhode Island§ — 0 1 — — — 0 7 — 2 — 1 7 — 5
Vermont§ — 0 1 — — — 0 1 1 3 1 1 5 5 3
Mid. Atlantic — 2 6 8 4 3 21 38 31 99 8 9 23 31 59
New Jersey — 0 2 — — — 2 11 — 24 — 0 0 — —
New York (Upstate) — 0 3 2 — — 4 27 6 13 8 7 22 31 25
New York City — 0 2 3 2 — 1 11 — — — 0 3 — —
Pennsylvania — 1 4 3 2 3 11 29 25 62 — 0 16 — 34
E.N. Central 1 2 10 10 19 28 50 100 178 349 — 2 19 3 5
Illinois — 1 4 3 4 — 11 29 — 94 — 1 9 — 1
Indiana — 0 3 2 2 — 6 15 3 52 — 0 7 — 1
Michigan — 0 5 2 2 8 14 40 58 78 — 1 6 1 3
Ohio 1 1 3 3 7 20 19 49 116 107 — 0 5 2 —
Wisconsin — 0 3 — 4 — 3 12 1 18 N 0 0 N N
W.N. Central — 1 6 3 8 3 30 357 44 250 — 7 18 11 13
Iowa — 0 2 1 1 — 3 10 1 24 — 0 3 — 1
Kansas — 0 2 — 2 — 4 12 7 19 — 1 6 6 7
Minnesota — 0 2 — 2 — 0 354 — — — 0 11 2 —
Missouri — 0 3 2 3 2 16 47 28 176 — 1 5 1 —
Nebraska§ — 0 1 — — 1 2 9 8 27 — 1 6 2 2
North Dakota — 0 1 — — — 0 12 — — — 0 7 — 1
South Dakota — 0 1 — — — 0 6 — 4 — 0 4 — 2
S. Atlantic 4 3 10 17 11 7 28 71 55 141 3 23 102 57 284
Delaware 1 0 1 2 — — 0 2 — 4 — 0 0 — —
District of Columbia — 0 0 — — — 0 1 — 2 — 0 0 — —
Florida 3 1 4 9 5 2 7 29 20 41 3 0 4 12 156
Georgia — 0 2 1 1 — 3 11 5 25 — 0 72 — 61
Maryland§ — 0 2 — — 5 2 8 11 7 — 7 15 17 25
North Carolina — 0 10 — 3 — 0 65 — 35 N 0 4 N N
South Carolina§ — 0 1 1 1 — 4 18 14 12 — 0 0 — —
Virginia§ — 0 2 4 1 — 3 14 4 15 — 10 26 22 37
West Virginia — 0 2 — — — 0 5 1 — — 3 6 6 5
E.S. Central — 0 4 2 1 2 13 30 46 81 — 1 6 — 16
Alabama§ — 0 2 — — — 4 19 12 13 — 0 0 — —
Kentucky — 0 1 2 — — 3 15 19 44 — 1 2 — 8
Mississippi — 0 1 — — — 1 6 — 11 — 0 1 — —
Tennessee§ — 0 2 — 1 2 3 9 15 13 — 0 4 — 8
W.S. Central 2 1 8 3 6 6 63 356 49 59 — 0 13 — 3
Arkansas§ 1 0 2 1 2 — 5 23 — 10 — 0 10 — 2
Louisiana — 0 3 — 2 — 1 8 — 10 — 0 0 — —
Oklahoma 1 0 2 1 — — 0 32 — 4 — 0 13 — 1
Texas§ — 1 6 1 2 6 55 354 49 35 — 0 1 — —
Mountain — 1 4 1 5 2 17 34 55 118 — 1 6 2 10
Arizona — 0 2 1 2 — 5 14 17 16 N 0 0 N N
Colorado — 0 3 — 1 2 4 10 12 29 — 0 0 — —
Idaho§ — 0 1 — 1 — 1 19 22 9 — 0 0 — —
Montana§ — 0 2 — — — 1 6 1 3 — 0 4 — 2
Nevada§ — 0 1 — 1 — 0 3 — 2 — 0 1 — —
New Mexico§ — 0 1 — — — 1 6 3 10 — 0 2 — 2
Utah — 0 1 — — — 3 16 — 49 — 0 2 — —
Wyoming§ — 0 2 — — — 0 5 — — — 0 4 2 6
Pacific 2 3 9 14 16 7 22 44 20 37 — 5 13 10 10
Alaska — 0 2 — 1 — 1 4 2 9 — 0 3 4 3
California 1 2 6 10 8 1 11 22 2 6 — 4 12 5 7
Hawaii — 0 1 — 1 — 0 3 — 2 — 0 0 — —
Oregon 1 0 6 4 3 4 4 14 14 17 — 0 3 1 —
Washington — 0 6 — 3 2 5 26 2 3 — 0 0 — —
American Samoa — 0 0 — — — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 1 — — 2 1 3 5 4
U.S. Virgin Islands — 0 0 — — — 0 0 — — N 0 0 N N
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 6, 2010, and February 7, 2009 (5th week)*
Reporting area
Salmonellosis Shiga toxin-producing E. coli (STEC)† Shigellosis
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 283 870 1,378 1,872 3,402 11 82 152 102 310 121 280 496 819 1,499
New England — 30 89 34 520 — 3 30 2 73 — 4 27 6 56
Connecticut — 0 20 20 406 — 0 1 1 65 — 0 4 4 40
Maine§ — 2 7 4 9 — 0 3 — — — 0 2 1 2
Massachusetts — 21 51 — 72 — 2 7 — 6 — 3 27 — 12
New Hampshire — 3 42 9 15 — 0 3 1 2 — 0 4 1 1
Rhode Island§ — 1 11 — 12 — 0 26 — — — 0 7 — 1
Vermont§ — 1 5 1 6 — 0 3 — — — 0 1 — —
Mid. Atlantic 33 89 206 217 342 1 6 21 12 23 21 55 87 130 290
New Jersey — 13 46 2 64 — 0 4 — 5 — 7 27 4 104
New York (Upstate) 24 23 72 67 67 1 3 9 5 7 3 4 16 13 7
New York City — 22 46 61 92 — 1 5 3 5 1 8 15 19 60
Pennsylvania 9 29 65 87 119 — 2 8 4 6 17 27 63 94 119
E.N. Central 24 89 152 157 475 — 15 36 12 55 8 44 78 63 403
Illinois — 24 52 24 114 — 3 9 1 21 1 11 34 15 77
Indiana — 5 19 — 30 — 1 8 — 5 — 1 5 — 8
Michigan 5 16 34 42 94 — 3 8 4 7 2 4 11 7 40
Ohio 19 24 52 80 149 — 2 11 4 9 5 17 46 37 220
Wisconsin — 12 30 11 88 — 5 21 3 13 — 6 26 4 58
W.N. Central 12 47 86 101 159 2 12 39 15 25 39 27 86 272 59
Iowa 1 7 16 8 19 — 2 14 — 8 — 0 5 7 24
Kansas — 6 22 15 26 — 1 5 3 1 1 3 13 14 20
Minnesota — 11 30 6 40 — 2 19 1 6 — 1 7 — 7
Missouri 8 12 30 57 45 2 2 10 8 6 38 18 72 250 5
Nebraska§ 3 5 41 13 14 — 1 6 3 4 — 0 3 1 2
North Dakota — 0 21 2 2 — 0 3 — — — 0 2 — —
South Dakota — 1 22 — 13 — 0 12 — — — 0 1 — 1
S. Atlantic 132 276 453 827 870 5 12 22 28 51 17 43 79 138 223
Delaware — 2 9 5 — — 0 2 — 1 — 3 10 12 3
District of Columbia — 0 5 2 4 — 0 0 — 1 — 0 2 1 2
Florida 78 133 278 392 356 3 3 7 11 16 11 9 18 48 63
Georgia 33 45 98 164 160 1 1 4 3 6 4 13 29 54 61
Maryland§ 6 15 32 45 64 — 2 5 8 9 1 6 19 7 28
North Carolina — 17 89 120 158 — 1 11 — 14 — 4 27 6 33
South Carolina§ 9 17 67 52 60 — 0 3 — 1 1 2 8 7 13
Virginia§ 3 20 48 39 62 1 2 7 6 3 — 3 12 3 19
West Virginia 3 4 23 8 6 — 0 5 — — — 0 3 — 1
E.S. Central 13 52 113 103 202 1 4 12 5 13 3 12 46 30 91
Alabama§ 3 14 39 34 70 — 1 4 4 2 — 2 9 4 30
Kentucky 3 7 18 26 38 — 1 4 — 5 2 3 25 18 9
Mississippi — 14 45 — 40 — 0 1 — — — 1 4 — 5
Tennessee§ 7 14 33 43 54 1 1 10 1 6 1 6 16 8 47
W.S. Central 9 94 216 48 176 — 5 15 6 6 17 48 149 75 169
Arkansas§ 1 10 25 9 33 — 1 4 2 2 1 6 14 6 16
Louisiana — 6 43 — 37 — 0 0 — — — 1 8 — 25
Oklahoma 8 11 30 19 18 — 0 6 1 1 4 5 19 11 15
Texas§ — 57 184 20 88 — 4 13 3 3 12 33 123 58 113
Mountain 16 53 130 154 240 — 9 26 11 38 5 18 49 48 113
Arizona 5 19 50 50 94 — 1 4 1 1 3 13 42 24 69
Colorado 6 10 33 48 49 — 3 13 3 25 2 2 6 14 15
Idaho§ 2 3 10 14 19 — 1 7 4 2 — 0 2 1 —
Montana§ 1 2 7 16 9 — 0 7 — — — 0 5 1 —
Nevada§ 2 3 11 9 16 — 0 3 1 1 — 1 7 1 14
New Mexico§ — 5 28 8 17 — 1 3 1 5 — 1 8 5 14
Utah — 6 14 4 34 — 1 11 1 3 — 0 3 2 1
Wyoming§ — 1 9 5 2 — 0 2 — 1 — 0 1 — —
Pacific 44 127 255 231 418 2 8 52 11 26 11 23 48 57 95
Alaska — 1 7 6 5 — 0 0 — — — 0 2 — —
California 31 95 150 180 323 1 5 15 8 23 9 19 41 51 87
Hawaii — 4 59 — 36 — 0 2 — 1 — 0 4 — 4
Oregon 2 8 19 29 32 — 1 11 2 — — 1 4 2 3
Washington 11 12 99 16 22 1 2 35 1 2 2 2 17 4 1
American Samoa — 0 0 — — — 0 0 — — — 1 2 — 1
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 6 21 13 49 — 0 0 — — — 0 2 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 6, 2010, and February 7, 2009 (5th week)*











Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States — 2 9 4 3 — 18 74 20 65
New England — 0 1 — — — 0 2 — 1
Connecticut — 0 0 — — — 0 0 — —
Maine§ — 0 0 — — — 0 2 — 1
Massachusetts — 0 0 — — — 0 1 — —
New Hampshire — 0 0 — — — 0 0 — —
Rhode Island§ — 0 0 — — — 0 0 — —
Vermont§ — 0 1 — — — 0 0 — —
Mid. Atlantic — 0 3 — — — 1 6 — —
New Jersey — 0 0 — — — 0 0 — —
New York (Upstate) — 0 1 — — — 0 3 — —
New York City — 0 1 — — — 0 4 — —
Pennsylvania — 0 2 — — — 0 2 — —
E.N. Central — 0 2 — 1 — 1 7 — 2
Illinois — 0 0 — — — 0 6 — 1
Indiana — 0 2 — — — 0 2 — —
Michigan — 0 1 — 1 — 0 1 — —
Ohio — 0 0 — — — 0 4 — 1
Wisconsin — 0 0 — — — 0 1 — —
W.N. Central — 0 3 — — — 3 27 — —
Iowa — 0 1 — — — 0 1 — —
Kansas — 0 1 — — — 0 0 — —
Minnesota — 0 1 — — — 0 1 — —
Missouri — 0 1 — — — 3 26 — —
Nebraska§ — 0 2 — — — 0 1 — —
North Dakota — 0 0 — — — 0 0 — —
South Dakota — 0 0 — — — 0 0 — —
S. Atlantic — 1 9 4 1 — 6 26 16 53
Delaware — 0 0 — — — 0 3 — —
District of Columbia — 0 0 — — — 0 0 — —
Florida — 0 1 — — — 0 2 — —
Georgia — 0 7 4 1 — 0 0 — —
Maryland§ — 0 2 — — — 0 3 — 5
North Carolina — 0 1 — — — 3 24 15 43
South Carolina§ — 0 1 — — — 0 4 1 3
Virginia§ — 0 1 — — — 0 5 — 2
West Virginia — 0 0 — — — 0 1 — —
E.S. Central — 0 2 — 1 — 3 15 — 7
Alabama§ — 0 2 — — — 1 7 — 3
Kentucky — 0 1 — — — 0 0 — —
Mississippi — 0 0 — 1 — 0 1 — —
Tennessee§ — 0 2 — — — 2 14 — 4
W.S. Central — 0 3 — — — 1 25 1 1
Arkansas§ — 0 0 — — — 0 14 — 1
Louisiana — 0 0 — — — 0 1 — —
Oklahoma — 0 3 — — — 0 24 — —
Texas§ — 0 1 — — — 0 3 1 —
Mountain — 0 2 — — — 0 1 3 1
Arizona — 0 1 — — — 0 1 3 —
Colorado — 0 1 — — — 0 0 — —
Idaho§ — 0 0 — — — 0 1 — —
Montana§ — 0 1 — — — 0 1 — —
Nevada§ — 0 0 — — — 0 0 — —
New Mexico§ — 0 0 — — — 0 1 — —
Utah — 0 0 — — — 0 0 — 1
Wyoming§ — 0 1 — — — 0 1 — —
Pacific — 0 1 — — — 0 0 — —
Alaska — 0 0 — — — 0 0 — —
California — 0 1 — — — 0 0 — —
Hawaii — 0 0 — — — 0 0 — —
Oregon — 0 0 — — — 0 0 — —
Washington — 0 0 — — — 0 0 — —
American Samoa — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — —
Guam — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Illnesses with similar clinical presentation that result from Spotted fever group rickettsia infections are reported as Spotted fever rickettsioses. Rocky Mountain spotted fever (RMSF) caused 
by Rickettsia rickettsii, is the most common and well-known spotted fever.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 6, 2010, and February 7, 2009 (5th week)*
Streptococcus pneumoniae,† invasive disease
Reporting area
All ages Age <5 Syphilis, primary and secondary
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 168 54 334 1,131 366 31 45 87 163 235 90 267 327 659 1,370
New England 3 1 50 34 6 — 1 23 3 8 3 6 17 26 30
Connecticut — 0 50 — — — 0 22 — — — 1 9 1 3
Maine§ — 0 4 6 1 — 0 2 1 — — 0 1 1 —
Massachusetts — 0 1 — — — 0 5 — 5 3 4 9 20 22
New Hampshire 2 0 6 17 2 — 0 2 2 2 — 0 1 1 5
Rhode Island§ — 0 4 — — — 0 1 — — — 0 5 3 —
Vermont§ 1 0 3 11 3 — 0 1 — 1 — 0 0 — —
Mid. Atlantic 11 3 22 66 15 4 5 23 24 10 28 34 50 148 177
New Jersey — 0 3 6 — — 0 4 4 3 2 3 13 13 24
New York (Upstate) 5 2 17 19 7 4 2 13 12 7 3 2 8 5 4
New York City — 0 1 — — — 0 11 — — 17 21 39 102 120
Pennsylvania 6 1 19 41 8 — 0 5 8 — 6 6 14 28 29
E.N. Central 17 13 58 153 69 3 7 15 20 45 1 25 46 41 130
Illinois — 0 0 — — — 1 4 — 9 — 12 33 3 69
Indiana 1 4 13 24 19 — 1 4 2 3 — 2 9 7 17
Michigan 4 0 22 47 4 — 1 4 6 5 1 4 13 22 23
Ohio 10 8 18 47 46 2 2 7 7 18 — 6 12 9 13
Wisconsin 2 0 10 35 — 1 1 3 5 10 — 0 3 — 8
W.N. Central 1 3 18 44 17 — 3 13 10 16 — 6 12 9 41
Iowa — 0 0 — — — 0 0 — — — 0 2 — 4
Kansas — 1 5 3 10 — 0 2 — 4 — 0 3 — 1
Minnesota — 0 13 13 — — 0 10 4 4 — 1 4 2 13
Missouri — 1 7 14 7 — 0 5 4 7 — 3 8 7 20
Nebraska§ 1 0 5 14 — — 0 2 2 — — 0 3 — 3
North Dakota — 0 3 — — — 0 3 — — — 0 1 — —
South Dakota — 0 2 — — — 0 2 — 1 — 0 1 — —
S. Atlantic 60 26 105 386 199 13 10 22 48 77 34 63 96 165 265
Delaware — 0 2 2 1 — 0 2 — — — 0 3 — 6
District of Columbia 1 0 1 4 — — 0 1 2 — 1 3 8 11 23
Florida 32 14 54 186 109 6 4 11 17 18 — 19 32 37 118
Georgia 13 8 25 56 76 3 3 10 15 28 — 14 51 1 18
Maryland§ 5 0 18 53 1 3 1 7 4 11 — 6 12 13 16
North Carolina — 0 0 — — — 0 0 — — 22 9 31 61 54
South Carolina§ 6 0 24 75 — — 1 4 8 11 1 2 6 14 8
Virginia§ — 0 0 — — — 0 4 — 7 10 6 15 28 21
West Virginia 3 1 13 10 12 1 0 3 2 2 — 0 2 — 1
E.S. Central 8 4 39 105 32 1 2 10 11 16 3 21 37 43 119
Alabama§ — 0 0 — — — 0 0 — — — 7 18 8 47
Kentucky 1 1 5 8 12 — 0 2 1 3 — 1 13 7 7
Mississippi — 0 1 — 1 — 0 2 — 3 — 4 12 2 14
Tennessee§ 7 2 37 97 19 1 2 9 10 10 3 8 14 26 51
W.S. Central 32 1 28 105 11 7 5 29 19 22 13 50 74 115 269
Arkansas§ 4 1 5 12 6 1 0 4 4 5 9 6 16 29 2
Louisiana — 0 5 — 5 — 0 4 — 5 2 12 27 15 105
Oklahoma 3 0 1 6 — 3 1 4 6 3 2 1 5 3 5
Texas§ 25 0 25 87 — 3 3 25 9 9 — 31 46 68 157
Mountain 34 2 74 217 15 3 5 12 23 34 2 8 18 10 42
Arizona 18 0 48 125 — 1 2 6 13 19 1 3 9 3 18
Colorado 14 0 20 68 — — 1 4 5 7 — 1 4 — 11
Idaho§ 1 0 0 1 — 1 0 2 1 — — 0 1 — —
Montana§ — 0 1 1 — — 0 0 — — — 0 1 — —
Nevada§ — 1 4 8 4 — 0 2 2 — 1 1 10 6 8
New Mexico§ 1 0 5 12 — 1 0 4 1 2 — 1 5 1 3
Utah — 1 5 1 8 — 1 6 1 6 — 0 2 — 2
Wyoming§ — 0 2 1 3 — 0 1 — — — 0 1 — —
Pacific 2 0 7 21 2 — 0 2 5 7 6 43 66 102 297
Alaska — 0 6 13 — — 0 2 4 5 — 0 0 — —
California 2 0 7 8 — — 0 1 1 — 1 39 56 87 272
Hawaii — 0 1 — 2 — 0 2 — 2 — 0 2 1 4
Oregon — 0 0 — — — 0 0 — — 1 1 5 4 3
Washington — 0 0 — — — 0 0 — — 4 2 7 10 18
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 3 17 17 12
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Includes drug resistant and susceptible cases of invasive Streptococcus pneumoniae disease among children <5 years and among all ages. Case definition: Isolation of S. pneumoniae from 
a normally sterile body site (e.g., blood or cerebrospinal fluid).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending February 6, 2010, and February 7, 2009 (5th week)*
West Nile virus disease†
Reporting area
Varicella (chickenpox) Neuroinvasive Nonneuroinvasive§
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 124 272 653 767 2,334 — 0 44 — — — 0 48 — —
New England 2 6 19 35 47 — 0 0 — — — 0 0 — —
Connecticut — 0 0 — — — 0 0 — — — 0 0 — —
Maine¶ — 0 15 23 — — 0 0 — — — 0 0 — —
Massachusetts — 0 2 — — — 0 0 — — — 0 0 — —
New Hampshire 2 3 10 12 29 — 0 0 — — — 0 0 — —
Rhode Island¶ — 0 1 — 2 — 0 0 — — — 0 0 — —
Vermont¶ — 0 4 — 16 — 0 0 — — — 0 0 — —
Mid. Atlantic 28 26 55 106 236 — 0 2 — — — 0 1 — —
New Jersey N 0 0 N N — 0 1 — — — 0 0 — —
New York (Upstate) N 0 0 N N — 0 1 — — — 0 1 — —
New York City — 0 0 — — — 0 1 — — — 0 0 — —
Pennsylvania 28 26 55 106 236 — 0 0 — — — 0 0 — —
E.N. Central 59 107 223 334 964 — 0 4 — — — 0 3 — —
Illinois — 26 73 — 229 — 0 3 — — — 0 0 — —
Indiana 7 7 30 25 46 — 0 1 — — — 0 1 — —
Michigan 17 39 84 139 296 — 0 1 — — — 0 0 — —
Ohio 35 31 86 149 308 — 0 0 — — — 0 2 — —
Wisconsin — 8 57 21 85 — 0 1 — — — 0 0 — —
W.N. Central 9 13 62 33 138 — 0 5 — — — 0 11 — —
Iowa N 0 0 N N — 0 0 — — — 0 1 — —
Kansas — 3 19 — 23 — 0 1 — — — 0 2 — —
Minnesota — 0 0 — — — 0 1 — — — 0 1 — —
Missouri 3 7 51 25 96 — 0 2 — — — 0 1 — —
Nebraska¶ N 0 0 N N — 0 2 — — — 0 6 — —
North Dakota 6 0 26 8 19 — 0 0 — — — 0 1 — —
South Dakota — 0 2 — — — 0 3 — — — 0 2 — —
S. Atlantic 23 24 109 130 205 — 0 4 — — — 0 1 — —
Delaware — 0 2 1 2 — 0 0 — — — 0 0 — —
District of Columbia — 0 3 — 2 — 0 0 — — — 0 0 — —
Florida 20 14 61 82 136 — 0 1 — — — 0 1 — —
Georgia N 0 0 N N — 0 1 — — — 0 0 — —
Maryland¶ N 0 0 N N — 0 0 — — — 0 1 — —
North Carolina N 0 0 N N — 0 0 — — — 0 0 — —
South Carolina¶ — 0 54 — 2 — 0 2 — — — 0 0 — —
Virginia¶ 1 0 6 7 27 — 0 1 — — — 0 0 — —
West Virginia 2 9 32 40 36 — 0 0 — — — 0 0 — —
E.S. Central — 8 29 15 62 — 0 6 — — — 0 4 — —
Alabama¶ — 8 27 15 62 — 0 0 — — — 0 0 — —
Kentucky N 0 0 N N — 0 1 — — — 0 0 — —
Mississippi — 0 2 — — — 0 5 — — — 0 4 — —
Tennessee¶ N 0 0 N N — 0 2 — — — 0 1 — —
W.S. Central — 71 261 29 383 — 0 17 — — — 0 6 — —
Arkansas¶ — 0 23 — 26 — 0 1 — — — 0 0 — —
Louisiana — 0 7 — 6 — 0 2 — — — 0 4 — —
Oklahoma N 0 0 N N — 0 2 — — — 0 2 — —
Texas¶ — 69 245 29 351 — 0 14 — — — 0 4 — —
Mountain 3 20 62 82 279 — 0 12 — — — 0 17 — —
Arizona — 0 0 — — — 0 4 — — — 0 2 — —
Colorado — 9 33 50 88 — 0 7 — — — 0 14 — —
Idaho¶ N 0 0 N N — 0 3 — — — 0 5 — —
Montana¶ — 0 16 — 54 — 0 1 — — — 0 1 — —
Nevada¶ N 0 0 N N — 0 2 — — — 0 1 — —
New Mexico¶ — 0 12 8 48 — 0 2 — — — 0 1 — —
Utah 3 8 32 24 89 — 0 1 — — — 0 1 — —
Wyoming¶ — 0 0 — — — 0 1 — — — 0 2 — —
Pacific — 1 5 3 20 — 0 12 — — — 0 12 — —
Alaska — 1 4 3 15 — 0 0 — — — 0 0 — —
California — 0 0 — — — 0 8 — — — 0 6 — —
Hawaii — 0 4 — 5 — 0 0 — — — 0 0 — —
Oregon N 0 0 N N — 0 1 — — — 0 4 — —
Washington N 0 0 N N — 0 6 — — — 0 3 — —
American Samoa N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 6 26 7 27 — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California 
serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.
§ Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE III. Deaths in 122 U.S. cities,* week ending February 6, 2010 (5th week)
Reporting area
All causes, by age (years)
P&I† 
Total Reporting area




Ages ≥65 45–64 25–44 1–24 <1
All  
Ages ≥65 45–64 25–44 1–24 <1
New England 606 420 135 30 10 11 62 S. Atlantic 1,294 869 281 85 34 24 84
Boston, MA 164 100 46 8 3 7 15 Atlanta, GA 184 110 42 17 8 7 8
Bridgeport, CT 33 25 6 1 — 1 6 Baltimore, MD 175 106 56 8 2 3 14
Cambridge, MA 19 18 1 — — — 3 Charlotte, NC 125 89 28 4 2 2 14
Fall River, MA 28 24 4 — — — 5 Jacksonville, FL 169 112 28 21 6 2 10
Hartford, CT 62 38 18 5 1 — 6 Miami, FL 169 117 35 12 4 — 11
Lowell, MA 24 21 3 — — — 1 Norfolk, VA 52 36 12 2 1 1 5
Lynn, MA 11 5 6 — — — — Richmond, VA 59 39 12 5 1 2 2
New Bedford, MA 19 12 4 2 1 — 1 Savannah, GA 85 62 15 6 — 2 2
New Haven, CT 42 29 9 4 — — 4 St. Petersburg, FL 45 35 5 2 3 — 7
Providence, RI 69 51 11 4 1 2 8 Tampa, FL 216 156 41 7 7 5 10
Somerville, MA 4 2 1 1 — — — Washington, D.C. U U U U U U U
Springfield, MA 40 29 9 1 1 — 6 Wilmington, DE 15 7 7 1 — — 1
Waterbury, CT 36 30 5 1 — — — E.S. Central 1,080 718 265 57 24 16 95
Worcester, MA 55 36 12 3 3 1 7 Birmingham, AL 197 134 43 9 8 3 22
Mid. Atlantic 1,915 1,345 413 104 32 21 92 Chattanooga, TN 72 47 20 5 — — 5
Albany, NY 35 25 9 — — 1 3 Knoxville, TN 109 77 25 6 — 1 5
Allentown, PA 16 14 1 1 — — — Lexington, KY 112 86 21 — 2 3 14
Buffalo, NY 84 60 18 3 1 2 9 Memphis, TN 233 146 60 14 9 4 22
Camden, NJ U U U U U U U Mobile, AL 109 78 25 5 — 1 8
Elizabeth, NJ 17 12 3 1 — 1 2 Montgomery, AL 45 32 9 3 1 — 2
Erie, PA 41 30 8 3 — — 7 Nashville, TN 203 118 62 15 4 4 17
Jersey City, NJ 14 7 4 2 1 — — W.S. Central 1,411 910 356 89 31 25 100
New York City, NY 1,038 743 213 53 19 10 40 Austin, TX 95 65 24 3 3 — 9
Newark, NJ 27 14 9 4 — — 2 Baton Rouge, LA U U U U U U U
Paterson, NJ 3 — 3 — — — — Corpus Christi, TX 57 35 16 5 — 1 8
Philadelphia, PA 378 249 93 25 6 5 14 Dallas, TX 192 112 55 14 5 6 9
Pittsburgh, PA§ U U U U U U U El Paso, TX 80 56 19 3 2 — 4
Reading, PA 33 25 4 2 1 1 3 Fort Worth, TX U U U U U U U
Rochester, NY 77 54 15 5 2 1 3 Houston, TX 429 271 108 33 8 9 28
Schenectady, NY 25 19 6 — — — 2 Little Rock, AR 93 56 28 5 2 2 9
Scranton, PA 33 25 7 — 1 — 1 New Orleans, LA U U U U U U U
Syracuse, NY 37 26 9 2 — — 2 San Antonio, TX 230 150 54 13 8 5 15
Trenton, NJ 24 17 7 — — — — Shreveport, LA 87 59 18 6 2 2 8
Utica, NY 15 14 — 1 — — 2 Tulsa, OK 148 106 34 7 1 — 10
Yonkers, NY 18 11 4 2 1 — 2 Mountain 1,010 685 233 61 18 12 68
E.N. Central 2,071 1,405 471 104 44 47 145 Albuquerque, NM 174 130 32 9 2 1 15
Akron, OH 61 43 14 1 2 1 9 Boise, ID 56 42 12 1 — 1 —
Canton, OH 33 20 12 1 — — 4 Colorado Springs, CO 59 37 16 4 2 — 2
Chicago, IL 251 166 54 13 13 5 6 Denver, CO 90 63 19 6 2 — 6
Cincinnati, OH 94 59 26 3 1 5 9 Las Vegas, NV 294 188 78 22 2 4 25
Cleveland, OH 238 181 40 12 2 3 8 Ogden, UT 49 30 14 5 — — 2
Columbus, OH 181 118 48 7 4 4 17 Phoenix, AZ U U U U U U U
Dayton, OH 147 97 40 4 3 3 15 Pueblo, CO 29 22 5 2 — — 2
Detroit, MI 204 113 63 17 5 6 10 Salt Lake City, UT 115 68 28 8 7 4 8
Evansville, IN 43 29 6 7 — 1 4 Tucson, AZ 144 105 29 4 3 2 8
Fort Wayne, IN 67 51 10 2 1 3 7 Pacific 1,638 1,145 340 101 21 30 158
Gary, IN 7 4 2 — 1 — 2 Berkeley, CA 17 16 1 — — — 2
Grand Rapids, MI 65 46 10 3 — 6 4 Fresno, CA 123 92 20 6 2 3 14
Indianapolis, IN 203 130 45 17 6 5 10 Glendale, CA 31 23 8 — — — 6
Lansing, MI 45 37 6 2 — — 4 Honolulu, HI 66 50 13 1 — 2 8
Milwaukee, WI 80 58 18 3 — 1 8 Long Beach, CA 73 45 23 4 — 1 9
Peoria, IL 50 34 12 2 1 1 7 Los Angeles, CA 257 146 64 31 8 8 26
Rockford, IL 73 52 16 3 — 2 3 Pasadena, CA 32 27 3 2 — — 3
South Bend, IN 73 52 17 3 1 — 4 Portland, OR 143 106 27 8 1 1 9
Toledo, OH 104 71 24 4 4 1 6 Sacramento, CA 198 140 44 9 3 2 22
Youngstown, OH 52 44 8 — — — 8 San Diego, CA 183 122 39 12 3 6 17
W.N. Central 558 353 144 33 16 12 40 San Francisco, CA 127 92 24 7 — 4 13
Des Moines, IA 108 78 24 4 1 1 9 San Jose, CA 198 150 31 12 3 2 20
Duluth, MN 32 24 7 1 — — 3 Santa Cruz, CA 20 16 4 — — — 3
Kansas City, KS U U U U U U U Seattle, WA U U U U U U U
Kansas City, MO 120 70 35 5 5 5 7 Spokane, WA 61 49 9 3 — — 2
Lincoln, NE 37 29 6 2 — — — Tacoma, WA 109 71 30 6 1 1 4
Minneapolis, MN 61 36 14 3 5 3 8 Total¶ 11,583 7,850 2,638 664 230 198 844
Omaha, NE 96 65 24 5 1 1 10
St. Louis, MO 50 12 23 11 3 1 —
St. Paul, MN 54 39 11 2 1 1 3
Wichita, KS U U U U U U U
U: Unavailable.   —: No reported cases.   
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and 
by the week that the death certificate was filed. Fetal deaths are not included.
† Pneumonia and influenza.
§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
¶ Total includes unknown ages.
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